<SEC-DOCUMENT>0001193125-24-268088.txt : 20241129
<SEC-HEADER>0001193125-24-268088.hdr.sgml : 20241129
<ACCEPTANCE-DATETIME>20241129160333
ACCESSION NUMBER:		0001193125-24-268088
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241125
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241129
DATE AS OF CHANGE:		20241129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Walgreens Boots Alliance, Inc.
		CENTRAL INDEX KEY:			0001618921
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				471758322
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36759
		FILM NUMBER:		241516459

	BUSINESS ADDRESS:	
		STREET 1:		108 WILMOT ROAD
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		(847) 315-2500

	MAIL ADDRESS:	
		STREET 1:		108 WILMOT ROAD
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d898694d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wba="http://walgreensbootsalliance.com/20241125" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-293">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-11-25_to_2024-11-25">0001618921</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="wba-20241125.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-11-25_to_2024-11-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-25</xbrli:startDate> <xbrli:endDate>2024-11-25</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-25</xbrli:startDate> <xbrli:endDate>2024-11-25</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-25</xbrli:startDate> <xbrli:endDate>2024-11-25</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-25</xbrli:startDate> <xbrli:endDate>2024-11-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-328">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt:datemonthdayyearen" id="ixv-329">November&#160;25, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-330">WALGREENS BOOTS ALLIANCE, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:stateprovnameen" id="ixv-331">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-332">001-36759</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-333">47-1758322</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-334">108 Wilmot Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-335">Deerfield</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:stateprovnameen" id="ixv-336">Illinois</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-337">60015</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-338">(847)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-339">315-3700</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:boolballotbox" id="ixv-340">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:boolballotbox" id="ixv-341">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:boolballotbox" id="ixv-342">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:boolballotbox" id="ixv-343">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Securities Exchange Act of 1934:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-344">Common Stock, $0.01 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-345">WBA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen" id="ixv-346">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" id="ixv-347">3.600% Walgreens Boots Alliance, Inc. notes due 2025</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" id="ixv-348">WBA25</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" format="ixt-sec:exchnameen" id="ixv-349">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" id="ixv-350">2.125% Walgreens Boots Alliance, Inc. notes due 2026</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" id="ixv-351">WBA26</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" format="ixt-sec:exchnameen" id="ixv-352">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-11-25_to_2024-11-25" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item</span><span style="text-decoration:underline">&#8201;</span><span style="text-decoration:underline">7.01</span>.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Regulation FD Disclosure</span>. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;10, 2024, the putative shareholder derivative plaintiff in Clem v. Skinner et al., No. <span style="white-space:nowrap"><span style="white-space:nowrap">1:21-cv-00406</span></span> (D. Del.), filed a filed a motion for preliminary approval of a settlement resolving the litigation. On November&#160;25, 2024, the court entered an order preliminarily approving the settlement. Pursuant to that preliminary approval order, Walgreens Boots Alliance, Inc. is attaching hereto as Exhibits 1 and 2, respectively, and incorporating by reference herein, (i)&#160;the Stipulation and Agreement of Settlement, dated July&#160;9, 2024, and (ii)&#160;the Notice of Pendency and Proposed Settlement of Shareholder Derivative Action, preliminarily approved by the court on November&#160;25, 2024. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item</span><span style="text-decoration:underline">&#8201;</span><span style="text-decoration:underline">9.01</span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Financial Statements and Exhibits</span>. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are included herewith: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center">Exhibit</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Description</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d898694dex991.htm">Stipulation and Agreement of Settlement, dated July&#160;9, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d898694dex992.htm">Notice of Pendency and Proposed Settlement of Shareholder Derivative Action, preliminarily approved by the court on November&#160;25, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">SIGNATURE </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">WALGREENS BOOTS ALLIANCE, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;29, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph B. Amsbary Jr.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Joseph B. Amsbary Jr.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President, Corporate Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d898694dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 2 of 59
PageID #: 244 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, JANICE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. ALMEIDA,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">-and-</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STIPULATION AND AGREEMENT OF SETTLEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stipulation and Agreement of Settlement dated as of July 9, 2024 (the &#147;Stipulation&#148;), is entered into between (a)&nbsp;James
Clem (&#147;Plaintiff&#148;); (b) individual defendants James A. Skinner, Stefano Pessina, William C. Foote, Nancy M. Schlichting, Ginger L. Graham, David J. Brailer, Janice M. Babiak, Dominic P. Murphy, John A. Lederer, Jos&eacute; E. Almeida,
George R. Fairweather, and Leonard D. Schaeffer (together, the &#147;Individual Defendants&#148;); and (c)&nbsp;nominal defendant Walgreens Boots Alliance, Inc. (&#147;Walgreens&#148; or the &#147;Company&#148; and, together with the Individual
Defendants, the &#147;Defendants&#148;) (collectively, the Plaintiff and Defendants, the &#147;Parties&#148;), by and through their respective counsel of record, and embodies the terms and conditions of the settlement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 3 of 59
PageID #: 245 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the above-captioned Derivative Action.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> This Stipulation, subject to the approval of the Court, is intended by the Parties to fully,
finally, and forever compromise, settle, release, resolve, and dismiss with prejudice the Released Claims (as defined below) upon and subject to the terms and conditions hereof, without any admission or concession as to the merits of any of the
Parties&#146; claims or defenses, and this Stipulation contains all of the relevant terms of the settlement of the Derivative Action. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Factual and Procedural Background </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. On March&nbsp;31, 2019, Counsel for Plaintiff (&#147;Plaintiff&#146;s Counsel&#148;), on behalf of Plaintiff, sent Walgreens a demand to
inspect certain of the Company&#146;s books and records pursuant to 8 <I>Del. C. </I>&#167; 220 related to, among other things, alleged false and misleading statements regarding a proposed merger between Walgreens and Rite Aid Corporation
(&#147;Rite Aid&#148;) (the &#147;Rite Aid Merger&#148;) (the &#147;Section&nbsp;220 Demand&#148;). The Section&nbsp;220 Demand also sought Company documents regarding matters unrelated to the Rite Aid Merger. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Following the execution of a confidentiality agreement, Walgreens produced 105 documents related to the Rite Aid Merger in response to the
Section&nbsp;220 Demand. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. On March 19, 2021, Plaintiff filed a stockholder derivative action captioned <I>Clem</I> <I>v. Skinner, et.
al</I>., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT> (the &#147;Derivative Action&#148;) in the United States District Court for the District of
Delaware (the &#147;Court&#148;) against Defendants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. On May 20, 2021, the Court entered an order staying the Derivative Action pursuant
to a joint stipulation filed by the Parties (the &#147;First Stipulation to Stay&#148;) until the earlier of (a)&nbsp;an entry of an order resolving all <FONT STYLE="white-space:nowrap">pre-trial</FONT> dispositive motions in a factually-related
securities class action captioned <I>Chabot, et al. v. Walgreens Boots Alliance, Inc., et al.</I>, No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:18-cv-02118</FONT></FONT> (M.D. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><A NAME="ex99_1898694_2"></A><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All otherwise undefined capitalized terms shall have the meaning ascribed to them in &para;21 herein.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 4 of 59
PageID #: 246 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pa.) (the &#147;Securities Action&#148;); or (b)&nbsp;the entry of an order of final approval of any settlement of the Securities Action and the expiration of any appeal deadlines or the
resolution of any appeal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Pursuant to the First Stipulation to Stay, and following the execution of a confidentiality agreement,
Defendants produced to Plaintiff 39 documents that Walgreens had produced to the plaintiffs in the Securities Action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. On March 31,
2023, the court before which the Securities Action is pending entered an order denying the parties&#146; cross-motions for summary judgment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. On April&nbsp;28, 2023, pursuant to a second joint stipulation filed by the Parties, the Court continued the stay of the Derivative Action
until the earlier of (a) 30 days following mediation in the Securities Action; or (b)&nbsp;entry of an order of final approval of any settlement of the Securities Action and the expiration of any appeal deadlines or the resolution of any appeal.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Following a series of mediations in which neither Plaintiff nor Plaintiff&#146;s Counsel participated, the parties in the Securities
Action settled that case, and on October&nbsp;23, 2023, the court before which the Securities Action is pending preliminarily approved that settlement. The Securities Action settlement received full and final court approval on February&nbsp;7, 2024,
and no party has appealed that court&#146;s order approving the settlement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. On October&nbsp;31, 2023, pursuant to a third joint
stipulation filed by the Parties, the Court entered a scheduling order governing the filing of an amended complaint and motion to dismiss in the Derivative Action (the &#147;Motion to Dismiss Scheduling Order&#148;). Before beginning briefing on the
anticipated motion to dismiss, the Parties commenced settlement negotiations, as detailed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 5 of 59
PageID #: 247 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. On December&nbsp;18, 2023, pursuant to a fourth joint stipulation filed by the Parties,
the Court ordered an extension of the deadlines set forth in the Motion to Dismiss Scheduling Order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. In light of the ongoing
settlement negotiations as described below, on January&nbsp;18, 2023, in response to a fifth joint stipulation filed by the Parties, the Court held in abeyance all deadlines set forth in the Motion to Dismiss Scheduling Order and ordered the Parties
to file a status update within 30 days. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Settlement Negotiations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Starting in or around October 2023, Plaintiff&#146;s Counsel and Counsel for Defendants (&#147;Defendants&#146; Counsel&#148; and,
collectively with Plaintiff&#146;s Counsel, &#147;Counsel&#148;) began to engage in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations regarding a potential resolution of the claims asserted in the Derivative Action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. Specifically, Plaintiff&#146;s Counsel sent to Defendants&#146; Counsel a Settlement Demand (the &#147;Settlement Demand&#148;) which
included, among other things, suggested corporate governance reforms that addressed the wrongdoing alleged in the Derivative Action. The Settlement Demand provided the basis for subsequent negotiations, which resulted in the execution of a
Settlement Term Sheet on January&nbsp;24, 2024. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. As consideration for the Settlement, Walgreens will institute certain corporate
governance reforms, the terms of which are stated in Exhibit A hereto (the &#147;Corporate Governance Reforms&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. After agreeing
to the Corporate Governance Reforms, the Parties negotiated at <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> the attorneys&#146; fees and reimbursement of expenses to be paid to Plaintiff&#146;s Counsel.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 6 of 59
PageID #: 248 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Attorneys&#146; fees and expenses are not the subject of any agreements between the Parties other than what is set forth in this Stipulation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PLAINTIFF&#146;S CLAIMS AND THE SETTLEMENT&#146;S BENEFITS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. Plaintiff believes that the claims asserted in the Derivative Action are meritorious, and Plaintiff&#146;s entry into this Stipulation and
Settlement is not intended to be and shall not be construed as an admission or concession concerning the relative strength or merit of the claims alleged in the Derivative Action. However, Plaintiff&#146;s Counsel recognizes and acknowledges the
expense and length of continued proceedings necessary to prosecute the Derivative Action against Defendants through trial and possible appeals. Plaintiff also has considered the uncertain outcome and the risk of any litigation, especially in complex
actions such as the Derivative Action, and the difficulties and delays inherent in such litigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. Plaintiff&#146;s Counsel have
conducted an investigation and analysis regarding the relevant facts, allegations, defenses, and controlling legal principles, including, <I>inter alia</I>: (i) reviewing Walgreens&#146; internal books and records regarding the alleged wrongdoing,
which were produced in connection with the 220 Demand; (ii)&nbsp;reviewing Walgreens&#146; press releases, public statements, U.S. Securities and Exchange Commission (&#147;SEC&#148;) filings, and securities analysts reports and advisories about the
Company, Rite Aid, and the Rite Aid Merger; (iii) reviewing related media reports about the Company, Rite Aid, and the Rite Aid Merger; (iv) researching applicable law with respect to the claims alleged in the Derivative Action and potential
defenses thereto; (v)&nbsp;preparing and filing the derivative complaint; and (vi)&nbsp;conducting damages analyses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. Based on
Plaintiff&#146;s Counsel&#146;s thorough review and analysis of the relevant facts, allegations, defenses, and controlling legal principles, Plaintiff believes that the Settlement set forth in this Stipulation is fair, reasonable, and adequate, and
confers substantial benefits upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 7 of 59
PageID #: 249 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Walgreens. Based upon Plaintiff&#146;s Counsel&#146;s evaluation, Plaintiff has determined that the Settlement is in the best interests of Plaintiff, Walgreens, and Current Walgreens Stockholders
(as defined below), and has therefore agreed to settle the Derivative Action upon the terms and subject to the conditions set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEFENDANTS&#146; DENIALS OF WRONGDOING AND LIABILITY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. Defendants have denied and continue to deny any and all fault, wrongdoing, and liability for the claims and damages asserted, or that
could have been asserted, in the Derivative Action and believe that their defenses to these claims are meritorious. Had the terms of this Stipulation not been reached, Defendants would have continued to contest Plaintiff&#146;s allegations
vigorously, and Defendants maintain that they had and have meritorious defenses to all claims alleged in the Derivative Action. However, Defendants recognize and acknowledge the expense and length of continued proceedings necessary to defend against
the claims asserted in the Derivative Action through trial and possible appeals. Defendants also have considered the uncertain outcome and the risk of any litigation, especially in complex actions such as the Derivative Action, and the difficulties
and delays inherent in such litigation. Accordingly, and without admitting the validity of any of the claims that Plaintiff has asserted in the Derivative Action or any liability with respect thereto, Defendants believe that the Settlement set forth
in this Stipulation is fair, reasonable, and adequate, and in the best interests of Walgreens and Current Walgreens Stockholders (as defined below). Neither this Stipulation, nor any of its terms or provisions, nor entry of the Judgment (as defined
below), nor any document or exhibit referred or attached to this Stipulation, nor any action taken to effect this Stipulation, is, may be construed as, or may be used as evidence of the validity of any of the Released Claims or any admission by or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 8 of 59
PageID #: 250 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against any of the Defendants of any fault, wrongdoing, or concession of liability, or any infirmity in the defenses that could have been asserted. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERMS OF STIPULATION AND AGREEMENT OF SETTLEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. The Parties, by and through their undersigned counsel, have agreed to the settlement, release, and dismissal with prejudice of any and all
claims that were asserted, or could have been asserted, against Defendants in or relating to the Derivative Action, on the terms and subject to the conditions set forth below, subject to Court approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <B><U>Definitions</U></B><B>:</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Stipulation and any exhibits attached hereto and made a part hereof, the following capitalized terms shall have the following
meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a. &#147;Board&#148; means Walgreens&#146;s Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b. &#147;Complaint&#148; means the Verified Stockholder Derivative Complaint for Breach of Fiduciary Duty and Violation of Securities Laws,
dated March&nbsp;19, 2021, filed in this Derivative Action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c. &#147;Current Walgreens Stockholders&#148; means, for purposes of this
Stipulation, any Persons who own Walgreens common stock as of the date of this Stipulation and who continue to hold their Walgreens common stock as of the date of the Settlement Hearing, excluding the Individual Defendants, the officers and
directors of Walgreens, and their Related Persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d. &#147;Defendants&#146; Counsel&#148; means the law firms of Abrams&nbsp;&amp;
Bayliss LLP and Ropes&nbsp;&amp; Gray LLP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e. &#147;Effective Date&#148; means the first date by which all of the events and conditions
specified in &para;36 herein have been met and have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 9 of 59
PageID #: 251 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">f. &#147;Fee and Expense Amount&#148; means any sum to be paid to Plaintiff&#146;s Counsel
for their attorneys&#146; fees and expenses incurred in connection with the Derivative Action, as detailed in <FONT STYLE="white-space:nowrap">&para;&para;30-31</FONT> herein, as approved by the Court. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">g. &#147;Final&#148; means the date upon which the last of the following shall occur with respect to the Judgment approving this Stipulation,
substantially in the form of Exhibit D attached hereto: (1)&nbsp;the expiration of the time to file a notice of appeal from the Judgment; or (2)&nbsp;if an appeal has been filed or if an appeal is taken, the court of appeals has either affirmed the
Judgment or dismissed that appeal and the time for any reconsideration or further appellate review has expired; or (3)&nbsp;if a higher court has granted further appellate review, that court has either affirmed the underlying Judgment or affirmed
the court of appeals&#146; decision affirming the Judgment or dismissing the appeal. For purposes of this paragraph, an &#147;appeal&#148; shall not include any appeal that concerns only the issue of attorneys&#146; fees and expenses or the payment
of a service award. Any proceeding or order, or any appeal or petition for a writ of certiorari pertaining solely to the application for attorneys&#146; fees, costs, or expenses, or the payment of a service award, shall not in any way delay or
preclude the Judgment from becoming Final. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">h. &#147;Judgment&#148; means the final order and judgment to be rendered by the Court,
substantially in the form attached as Exhibit D hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i. &#147;Notice&#148; means the notice to Current Walgreens Stockholders of the
Settlement, substantially in the form attached as Exhibit B hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">j. &#147;Person(s)&#148; means an individual, corporation,
partnership, limited partnership, limited liability company, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, and any business or legal
entity, and his, her, its, or their spouses, heirs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 10 of
59 PageID #: 252 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predecessors, administrators, successors, parents, subsidiaries, affiliates, representatives, or assignees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">k. &#147;Plaintiff&#146;s Counsel&#148; means the law firms of Cooch and Taylor, P.A., and Robbins LLP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">l. &#147;Preliminary Approval Order&#148; means the order, substantially in the form attached hereto as Exhibit C, to be entered by the Court
preliminarily approving the Settlement, directing that notice of the Settlement be provided to Current Walgreens Stockholders, and scheduling the Settlement Hearing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">m. &#147;Related Persons&#148; means: (i)&nbsp;with regard to any individual, the individual&#146;s spouses, marital communities, immediate
family members, heirs, executors, personal representatives, estates, administrators, trusts, beneficiaries, distributees, foundations, agents, employees, fiduciaries, partners, partnerships, general or limited partners of partnerships, joint
ventures, member firms, limited liability companies, corporations, predecessors, successors, and assigns or other individual or entity in which such individual has a controlling interest, and each and all of their respective past and present
officers, directors, employees, agents, affiliates, parents, subsidiaries, divisions, attorneys, accountants, auditors, advisors, insurers, <FONT STYLE="white-space:nowrap">co-insurers,</FONT> <FONT STYLE="white-space:nowrap">re-insurers,</FONT>
heirs, executors, personal representatives, estates, administrators, trusts, predecessors, successors, assigns, financial or investment advisors, advisors, consultants, investment bankers, entities providing any fairness opinion, underwriters,
brokers, dealers, lenders, and commercial bankers; and (ii)&nbsp;with regard to any entity (i.e., <FONT STYLE="white-space:nowrap">non-individual),</FONT> including Walgreens, the entity&#146;s past or present agents, officers, directors, attorneys,
accountants, auditors, advisors, insurers, <FONT STYLE="white-space:nowrap">co-insurers,</FONT> <FONT STYLE="white-space:nowrap">re-insurers,</FONT> consultants, partners, controlling stockholders, joint venturers, fiduciaries, partners,
partnerships, general or limited partners of partnerships, joint ventures, member firms, limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 11 of
59 PageID #: 253 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liability companies, corporations, related or affiliated entities, employees, affiliates, predecessors, successors, parents, subsidiaries, and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">n. &#147;Released Claims&#148; means all claims, disputes, demands, losses, costs, interest, penalties, fees, attorneys&#146; fees, expert or
consulting fees, expenses, rights, actions or causes of action, duties, obligations, judgments, debts, sums of money due, suits, agreements, promises, damages, matters, liabilities, losses, issues and charges of any kind, and claims for relief of
every nature and description whatsoever, including both known claims and Unknown Claims (as defined below), whether direct or indirect, representative, class, derivative, individual, asserted or unasserted, matured or unmature, accrued or unaccrued,
foreseen or unforeseen, disclosed or undisclosed, discoverable and undiscoverable, concealed or hidden, liquidated or unliquidated, contingent or fixed or vested, at law or equity, regardless of legal or equitable theory, and whether arising under
federal or state statutory or common law or any other law, rule, ordinance, administrative provision or regulation, whether foreign or domestic, that (i)&nbsp;were or could have been asserted in the Derivative Action or the Securities Action;
(ii)&nbsp;arise out of, are based upon, or relate in any way to any of the allegations, acts, transactions, facts, events, matters, occurrences, statements, representations, misrepresentations or omissions involved, set forth, alleged or referred
to, in this Derivative Action, the Complaint, or the Securities Action; (iii)&nbsp;would have been barred by <I>res judicata </I>had the Derivative Action been litigated to a final judgment; or (iv)&nbsp;arise out of, relate to, or concern the
defense, settlement, or resolution of the Derivative Action, except claims to enforce any terms of this Stipulation. For the avoidance of doubt, the Released Claims include any claims pursuant to the Private Securities Litigation Reform Act for
contribution/indemnity or claims that are otherwise dependent on liability in this Derivative Action or the Securities Action as against any Defendant or Related Persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 12 of
59 PageID #: 254 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">o. &#147;Released Defendants&#146; Claims&#148; means all claims, demands, rights,
liabilities, losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys&#146; fees, actions, potential actions, causes of action, suits, judgments, decrees, matters, as well as issues and
controversies of any kind, whether known or unknown, whether disclosed or undisclosed, whether accrued or unaccrued, apparent or unapparent, foreseen or unforeseen, suspected or unsuspected, fixed or contingent, whether based on federal, state,
local, statutory, or common law or any other law, rule, or regulation, including Unknown Claims (as defined below), that have been or could have been asserted in the Derivative Action or any forum by Defendants or Released Parties against any of
Plaintiff and Plaintiff&#146;s Counsel, which arise out of or are related in any way to the institution, prosecution, defense, or settlement of the Derivative Action; provided, however, that the Released Defendants&#146; Claims shall not include the
right to enforce this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">p. &#147;Released Parties&#148; means, whether or not each or all of the following persons or entities
were named in the Derivative Action or any related suit: (i)&nbsp;any and all Defendants (including Walgreens and the Individual Defendants); and (ii)&nbsp;the Related Persons of each and all of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">q. &#147;Settlement&#148; means the resolution of the Derivative Action on the terms and conditions set forth in this Stipulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">r. &#147;Settlement Hearing&#148; means the hearing by the Court to review the adequacy, fairness, and reasonableness of the Settlement set
forth in this Stipulation and to determine (i)&nbsp;whether to enter the Judgment; (ii)&nbsp;the amount of Plaintiff&#146;s Counsel&#146;s attorneys&#146; fees and expenses; and (iii)&nbsp;all other matters properly before the Court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 13 of
59 PageID #: 255 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">s. &#147;Unknown Claims&#148; means any claims that a Person releasing claims does not know
of or suspect exist in their favor, or in favor of Walgreens either derivatively or directly, at the time of the release of the Released Claims or Released Defendants&#146; Claims as against the Released Parties (or such other Related Persons),
including those claims which, if known, might have affected the decision to enter into this Stipulation. With respect to any of the Released Claims and Released Defendants&#146; Claims, the Parties stipulate and agree that, upon the Effective Date,
each Party, and each Current Walgreens Stockholder, expressly has waived, relinquished, and released any and all provisions, rights, and benefits conferred by or under California Civil Code &#167; 1542 or any law of the United States or any state of
the United States, or principle of common law, that is similar, comparable, or equivalent to California Civil Code &#167; 1542, which provides: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE
TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties acknowledge, and the Current Walgreens Stockholders by operation of law shall be deemed to have acknowledged, that they may discover facts in
addition to or different from those now known or believed to be true with respect to the Released Claims and Released Defendants&#146; Claims, but that it is the intention of the Parties to completely, fully, finally, and forever extinguish any and
all Released Claims and Released Defendants&#146; Claims, known or unknown, suspected or unsuspected, which now exist, or previously existed, or may hereafter exist, and without regard to the subsequent discovery of additional or different facts.
The Parties acknowledge that the inclusion of &#147;Unknown Claims&#148; in the definitions of &#147;Released Claims&#148; and &#147;Released Defendants&#146; Claims&#148; was separately bargained for, was a material element of the Settlement, and
was relied upon by each and all of the Parties in entering into this Stipulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 14 of
59 PageID #: 256 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <B><U>Terms of the Settlement</U></B>: As a result of the filing, prosecution, and
settlement of the Derivative Action, and without admitting any alleged wrongdoing, the Company or Board, as appropriate, shall implement the Corporate Governance Reforms identified in Exhibit A. Specifically, no later than 90 days after the
Effective Date, the Company or Board shall take such actions as necessary to adopt, implement, and/or initiate, as appropriate, the Corporate Governance Reforms, and shall ensure adherence to the Corporate Governance Reforms for the period stated in
Exhibit A. However, Walgreens shall not be required to implement or maintain the Corporate Governance Reforms to the extent that (a)&nbsp;Walgreens ceases to be a public company that is required to file reports with the United States Securities and
Exchange Commission (the &#147;SEC&#148;); or (b)&nbsp;doing so conflicts (now or in the future) with any rule, law, or regulation, including regulations of any stock exchange on which Walgreens securities are listed (although these limits shall not
affect or eliminate Walgreens&#146;s obligations to implement and/or maintain any remaining Corporate Governance Reforms that do not create any such conflicts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Walgreens and the Board acknowledge that the filing and prosecution of the Derivative Action caused the Company&#146;s decision to adopt and
implement the Corporate Governance Reforms. Walgreens and the Board also acknowledge and agree that the Corporate Governance Reforms confer a substantial benefit to Walgreens and Walgreens&#146; stockholders. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SETTLEMENT ADMINISTRATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. As soon as practicable after execution of this Stipulation, Plaintiff shall submit this Stipulation, together with its exhibits, to the
Court and apply for entry of the Preliminary Approval Order in this Court, substantially in the form of Exhibit C attached hereto, requesting, inter alia: (a) preliminary approval of the Settlement set forth in this Stipulation; (b)&nbsp;approval of
the method of providing notice of the proposed Settlement to Current Walgreens Stockholders; (c)&nbsp;approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 15 of
59 PageID #: 257 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the form of notice substantially in the form of Exhibit B attached hereto; and (d)&nbsp;a date for the Settlement Hearing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. Walgreens shall undertake the administrative responsibility for giving notice of the Settlement to Current Walgreens Stockholders and shall
be solely responsible for paying the costs and expenses related to providing such notice to its stockholders. Within 20 business days after the Court&#146;s entry of the Preliminary Approval Order, Walgreens shall cause the Stipulation and the
Notice to be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished to the SEC, and Walgreens shall post a link to the Stipulation and the Notice on the &#147;Investor Relations&#148; page of Walgreens&#146; website, and shall
maintain that link through the date of the Settlement Hearing. If additional notice is required by the Court, then the cost and administration of such additional notice will be borne by Walgreens. The Parties believe the content of the Notice and
the notice procedures set forth in this paragraph constitute adequate and reasonable notice to Current Walgreens Stockholders pursuant to applicable law and due process. Prior to the Settlement Hearing, Defendants&#146; Counsel shall file with the
Court an appropriate declaration with respect to compliance with this paragraph. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. Plaintiff shall request that the Court hold the
Settlement Hearing at least 60 calendar days after the deadline to provide notice of the Settlement as described in &para;24 above to Current Walgreens Stockholders, to approve the Settlement and the Fee and Expense Amount to be paid to
Plaintiffs&#146; Counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. Pending the Court&#146;s determination as to the final approval of the Settlement, Plaintiff and
Plaintiff&#146;s Counsel, and any Current Walgreens Stockholders, derivatively on behalf of Walgreens, are barred and enjoined from commencing, prosecuting, instigating, or in any way participating in the commencement or prosecution of any action
asserting any Released Claims against any of the Released Parties in any court or tribunal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 16 of
59 PageID #: 258 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RELEASES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. Upon the Effective Date, Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of
the Judgment shall have, fully, finally, and forever released, relinquished, and discharged the Released Claims against the Released Parties and their Related Persons. Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be
deemed to have, and by operation of the Judgment shall have, covenanted not to sue any Released Party or any of their Related Persons with respect to any Released Claims, and shall be permanently barred and enjoined from instituting, commencing, or
prosecuting the Released Claims against any Released Party or any of their Related Persons or Defendants&#146; Counsel except to enforce the releases and other terms and conditions contained in this Stipulation and/or the Judgment entered pursuant
thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. Upon the Effective Date, each of Walgreens and the Individual Defendants shall be deemed to have, and by operation of the
Judgment shall have, fully, finally, and forever released, relinquished, and discharged each and all of Plaintiff and Plaintiff&#146;s Counsel from the Released Defendants&#146; Claims. Walgreens and the Individual Defendants shall be deemed to
have, and by operation of the Judgment shall have, covenanted not to sue Plaintiff or Plaintiff&#146;s Counsel with respect to any Released Defendants&#146; Claims, and shall be permanently barred and enjoined from instituting, commencing, or
prosecuting Released Defendants&#146; Claims against Plaintiff or Plaintiff&#146;s Counsel except to enforce the releases and other terms and conditions contained in this Stipulation and/or the Judgment entered pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. Nothing herein shall in any way release, waive, impair, or restrict the rights of any of the Parties to enforce the terms of this
Stipulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 17 of
59 PageID #: 259 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PLAINTIFF&#146;S COUNSEL&#146;S ATTORNEYS&#146; FEES AND EXPENSES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. After negotiating the Corporate Governance Reforms, Plaintiff&#146;s Counsel and Defendants&#146; Counsel separately negotiated the amount
of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel in recognition of the benefit provided to Walgreens and Walgreens&#146; stockholders due to the Corporate Governance Reforms. The Parties have agreed that, subject to Court
approval, Walgreens shall pay attorneys&#146; fees and expenses to Plaintiff&#146;s Counsel in the total amount of $750,000, which shall be Plaintiff&#146;s Counsel&#146;s sole entitlement to an award of fees and expenses in connection with the
Derivative Action (the &#147;Fee and Expense Amount&#148;). The Fee and Expense Amount shall cover all fees and expenses for Plaintiff in the Derivative Action. Plaintiff and Plaintiff&#146;s Counsel agree not to request that any greater amount be
awarded to Plaintiff&#146;s Counsel by the Court. Any order or proceeding related to the Fee and Expense Amount, or any appeal from any order relating thereto, or any reversal or modification thereof, shall have no effect on the Settlement and shall
not operate to, or be grounds to, terminate or cancel the Settlement or to affect or delay the finality of the Judgment or dismissal of the Derivative Action with prejudice. Plaintiff and Plaintiff&#146;s Counsel may not cancel or terminate this
Stipulation or the Settlement based on the Court&#146;s or any appellate court&#146;s ruling with respect to attorneys&#146; fees or expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31. Walgreens shall cause the Fee and Expense Amount to be paid, to the extent approved by the Court, into an escrow account designated by
Plaintiff&#146;s Counsel (the &#147;Escrow Account&#148;), for Plaintiff&#146;s Counsel&#146;s attorneys&#146; fees and expenses. Walgreens shall fund the Escrow Account with the Fee and Expense Amount, via wire transfer or check at the option of
Walgreens, within 30 business days following the later of: (a)&nbsp;the Court&#146;s entry of the Preliminary Approval Order; (b)&nbsp;the transmission to Defendants&#146; Counsel of payee information for that account, including the tax
identification number, Form <FONT STYLE="white-space:nowrap">W-9,</FONT> and other information that may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 18 of
59 PageID #: 260 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by Walgreens to facilitate payment of the Fee and Expense Amount; or (c)&nbsp;August&nbsp;1, 2024. Plaintiff&#146;s Counsel shall be solely responsible for any administrative costs
associated with the Escrow Account as well as the filing of all informational and other tax returns with the Internal Revenue Service, or any other state or local taxing authority, as may be necessary or appropriate. Neither Defendants nor
Defendants&#146; Counsel shall have responsibility for, nor bear any risk or liability with respect to, the Escrow Account, its operation, and any taxes or expenses incurred in connection with the Escrow Account. No fees or expenses shall be paid to
Plaintiff&#146;s Counsel pursuant to this Stipulation absent approval by the Court of a complete release of all Released Parties and their Related Persons, in the form provided herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32. The Fee and Expense Amount shall remain in the Escrow Account until the entry of an order finally approving the Settlement or
September&nbsp;1, 2024, whichever is later, at which time the Fee and Expense Amount shall immediately be releasable to Plaintiff&#146;s Counsel, notwithstanding the existence of any timely filed objections thereto or potential for appeal therefrom,
or collateral attack on the Settlement or any part thereof. Should the Court order the payment of attorneys&#146; fees and expenses to Plaintiff&#146;s Counsel in an amount less than the agreed Fee and Expense Amount prior to, or at the time of,
entry of the Judgment, then only the Court-approved amount shall be released to Plaintiff&#146;s Counsel. Any amounts remaining in the Escrow Account shall be returned to Defendants within 20 calendar days following release of the Fee and Expense
Amount from the Escrow Account. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33. Payment of the Fee and Expense Amount in the amount approved by the Court shall constitute final and
complete payment for Plaintiff&#146;s Counsel&#146;s attorneys&#146; fees and expenses that have been incurred or will be incurred in connection with the filing and prosecution of the Derivative Action and the resolution of the claims alleged
therein. Defendants and Defendants&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 19 of
59 PageID #: 261 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Counsel shall have no responsibility for the allocation or distribution of the Fee and Expense Amount amongst Plaintiff&#146;s Counsel. Defendants shall have no obligation to make any payment to
any Plaintiff&#146;s Counsel other than as provided in &para;&para;30 and 31 herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">34. If for any reason any condition in &para;36 is
not met and the Effective Date of this Stipulation does not occur, if the Stipulation is in any way canceled or terminated, if the Fee and Expense Amount does not become Final, if the Fee and Expense Amount is reduced or reversed, or if the Judgment
is reversed or substantially modified on appeal, then each of Plaintiff&#146;s Counsel and their successors shall be severally obligated to repay to Walgreens, within 20 calendar days, any portion of the Fee and Expense Amount that Plaintiff&#146;s
Counsel received and that was ultimately not awarded to them. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35. Except as otherwise provided herein or except as provided pursuant to
indemnification or insurance rights, each of the Parties shall bear his, her, or its own costs and attorneys&#146; fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS OF
SETTLEMENT, EFFECT OF DISAPPROVAL, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CANCELLATION, OR TERMINATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36. The Effective Date of the Stipulation shall be conditioned on the occurrence of all of the following events: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the entry of the Preliminary Approval Order, in substantially the form attached as Exhibit C hereto;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice of the Settlement is disseminated in accordance with the Preliminary Approval Order;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court&#146;s entry of the Judgment, in substantially the form attached as Exhibit D hereto; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Judgment has become Final. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 20 of
59 PageID #: 262 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">37. If any of the conditions specified in &para;36 are ultimately not met, then the
Stipulation shall be canceled and terminated subject to &para;39, and Plaintiff and Defendants shall be restored to their respective positions in the Derivative Action as of the date immediately preceding the date of this Stipulation, unless
Plaintiff&#146;s Counsel and Defendants&#146; Counsel mutually agree in writing to proceed with this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">38. Each of the Parties
shall have the right to terminate the Settlement by providing written notice of their election to do so to all other Parties within 20 calendar days of the date on which (a)&nbsp;the Court refuses to approve this Stipulation, or the terms contained
herein, in any material respect; (b)&nbsp;the Preliminary Approval Order is not entered in substantially the form attached as Exhibit C hereto; (c)&nbsp;the Judgment is not entered in substantially the form attached as Exhibit D hereto; (d)&nbsp;the
Judgment is reversed or substantially modified on appeal, reconsideration or otherwise; (e)&nbsp;the payment of the Fee and Expense Amount in accordance with &para;&para;30 and 31 herein is not made; or (f)&nbsp;the Effective Date of the Settlement
cannot otherwise occur; except that such termination shall not be effective unless and until the terminating Party has, within 20 calendar days of the date on which notice of the termination event has been provided to all other Parties, attempted in
good faith to confer with the other Parties to attempt to remedy the issue that has precipitated the notice to terminate. Any order or proceeding related to the Fee and Expense Amount, or any appeal from any order relating thereto or reversal or
modification thereof, shall not operate to cancel this Stipulation, allow for the termination of the Settlement, or affect or delay the finality of the Judgment approving the Settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">39. If for any reason the Effective Date of this Stipulation does not occur, or the Settlement is terminated for any reason, including pursuant
to &para;38 above, Plaintiff and Defendants shall be restored to their respective positions as of the date immediately preceding the date of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 21 of
59 PageID #: 263 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stipulation, and all negotiations, proceedings, documents prepared, and statements made in connection herewith shall be without prejudice to the Parties, shall not be deemed or construed to be an
admission by any of the Parties of any act, matter, or proposition, and shall not be used in any manner for any purpose in any subsequent proceeding in the Derivative Action or in any other action or proceeding. In such event, the terms and
provisions of this Stipulation, with the exception of &para;&para;21, 34, 39, and <FONT STYLE="white-space:nowrap">44-62</FONT> herein, shall have no further force and effect with respect to the Parties and shall not be used in the Derivative Action
or in any other action or proceeding for any purpose, and any judgment or orders entered by the Court in accordance with the terms of this Stipulation shall be treated as vacated. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40. The Parties (a)&nbsp;acknowledge that it is their intent to consummate this Stipulation; and (b)&nbsp;agree to cooperate to the extent
reasonably necessary to effectuate and implement all terms and conditions of this Stipulation and to exercise their best efforts to accomplish the foregoing terms and conditions of this Stipulation. If any disputes arise out of the finalization of
the Settlement, the Parties shall first meet and confer in an effort to resolve any disputes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41. The Parties agree that the terms of the
Settlement were negotiated in good faith and at arm&#146;s length by the Parties and reflect a Settlement that was reached voluntarily based upon adequate information and after consultation with competent legal counsel. The Parties shall not take
the position that the litigation was brought or defended in bad faith. The Parties and their respective counsel agree that (a)&nbsp;throughout the course of the litigation, all Parties and their counsel complied with Rule 11 of the Federal Rules of
Civil Procedure in connection with the maintenance, prosecution, defense, and settlement of the Derivative Action; and (b)&nbsp;they shall not make any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 22 of
59 PageID #: 264 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application for sanctions, pursuant to Rule 11 or other court rule or statute, with respect to the Derivative Action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42. While maintaining their positions that the claims and defenses asserted in the Derivative Action are meritorious, Plaintiff and
Plaintiff&#146;s Counsel, on the one hand, and Defendants and Defendants&#146; Counsel, on the other, shall not make any public statements or statements to the media (whether or not for attribution) that disparage the Settlement or any of the
others&#146; business, conduct, or reputation, or that of their counsel. Notwithstanding the foregoing, each of the Parties reserves their right to rebut, in a manner that such Party determines to be reasonable and appropriate, any contention made
in any public forum that the Derivative Action was brought or defended in bad faith or without a reasonable basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">43. Pending the
Effective Date, the Parties agree not to initiate any proceedings concerning the Released Claims other than those incident to the Settlement itself; provided, however, that Defendants may seek to prevent, dismiss, or stay any other action or claims
brought seeking to assert any Released Claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">44. Whether or not the Settlement is approved by the Court, and whether or not the
Settlement is consummated, the fact and terms of this Stipulation, including any exhibits attached hereto, all proceedings in connection with the Settlement, and any act performed or document executed pursuant to or in furtherance of this
Stipulation or the Settlement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a. shall not be offered, received, or used in any way against the Parties as evidence of, or be deemed to
be evidence of&#151;or a presumption, concession, or admission by any of the Parties with respect to the truth of&#151;any fact alleged by Plaintiff or the validity, or lack thereof, of any claim that has been or could have been asserted in the
Derivative Action or in any litigation, or the deficiency, infirmity, or validity of any defense that has been or could have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 23 of
59 PageID #: 265 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserted in the Derivative Action or in any litigation, or of any fault, wrongdoing, negligence, or liability of any of the Released Parties; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b. shall not be offered, received, or used in any way against any of the Released Parties as evidence of, or be deemed to be evidence of, a
presumption, concession, or admission of any fault, misrepresentation, or omission with respect to any statement or written document approved, issued, or made by any Released Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c. shall not be offered, received, or used in any way against any of the Released Parties as evidence of, or be deemed to be evidence of, a
presumption, concession, or admission of any liability, fault, negligence, omission or wrongdoing, or in any way referred to for any other reason as against the Released Parties, in any arbitration proceeding, or in any other civil, criminal, or
administrative action or proceeding in any court, administrative agency, or other tribunal; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d. shall not be offered, received, or used
in any way against Plaintiff or Plaintiff&#146;s Counsel as evidence of, or be deemed to be evidence of, a presumption, concession, or admission that any of Plaintiff&#146;s claims are without merit or that Plaintiff would not have been able to
prevail on their claims at trial. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">45. Neither this Stipulation nor the Settlement, nor any act performed or document executed pursuant to
or in furtherance of this Stipulation, or the Settlement, shall be admissible in any proceeding for any purpose, except to enforce the terms of the Settlement; provided, however, that the Released Parties may refer to the Settlement, and file this
Stipulation and/or the Judgment, in any action that may be brought against them to effectuate the liability protections granted them hereunder, including, without limitation, to support a defense or claim based on principles of <I>res judicata</I>,
collateral estoppel, full faith and credit, release, standing, good faith settlement, judgment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 24 of
59 PageID #: 266 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bar or reduction, contribution and/or indemnity pursuant to the Private Securities Litigation and Reform Act, or any other theory of claim preclusion or issue preclusion or similar defense or
claim under U.S. federal or state law or foreign law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">46. The exhibits to this Stipulation are material and integral parts hereof and are
fully incorporated herein by this reference. In the event that there exists a conflict or inconsistency between the terms of this Stipulation and the terms of any exhibit hereto, the terms of this Stipulation shall prevail. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">47. This Stipulation may be amended or modified only by a written instrument signed by or on behalf of all of the Parties or their respective <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest.</FONT></FONT> After prior notice to the Court, but without further order of the Court, the Parties may agree to reasonable extensions of time to carry out any
provisions of this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">48. This Stipulation and the exhibits attached hereto represent the complete and final resolution of all
disputes among the Parties with respect to the Derivative Action, constitute the entire agreement among the Parties with respect to the Settlement, and supersede any and all prior negotiations, discussions, agreements, or undertakings, whether oral
or written, with respect to such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">49. The waiver by one Party of any breach of this Stipulation by any other Party shall not be
deemed a waiver of any other prior or subsequent breach of this Stipulation. The provisions of this Stipulation may not be waived except by a writing signed by the affected Party, or counsel for that Party. Any failure by any Party to this
Stipulation to insist upon the strict performance by any other Party of any of the provisions of the Stipulation shall not be deemed a waiver of any of the provisions, and such Party, notwithstanding such failure, shall have the right thereafter to
insist </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 25 of
59 PageID #: 267 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the strict performance of any and all of the provisions of the Stipulation to be performed by such other Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">50. The headings in this Stipulation and its exhibits are used for the purpose of convenience only and are not meant to have legal effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">51. This Stipulation and the exhibits attached hereto shall be considered to have been negotiated, executed, and delivered, and to be wholly
performed, in the State of Delaware, and the rights and obligations of the Parties to this Stipulation shall be construed and enforced in accordance with, and governed by, the internal, substantive laws of the State of Delaware without giving effect
to that state&#146;s choice of law principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">52. This Stipulation and the Settlement shall be binding upon, and inure to the benefit of,
the successors and assigns of the Parties and their Related Persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">53. No representations, warranties, or inducements have been made to
any Party concerning this Stipulation or its exhibits other than the representations, warranties, and covenants contained and memorialized in such documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">54. This Stipulation shall not be construed more strictly against one Party than another merely by virtue of the fact that it, or any part of
it, may have been prepared by counsel for one of the Parties, the Parties recognizing that this Stipulation is the result of <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations among the Parties and all Parties have contributed
substantially and materially to the preparation of this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">55. All agreements made and orders entered during the course of the
Derivative Action relating to the confidentiality of information and documents shall survive this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">56. Nothing in this
Stipulation, the Settlement or the negotiations or proceedings relating to the Settlement is intended to or shall be deemed to constitute a waiver of any applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 26 of
59 PageID #: 268 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
privilege or immunity, including, without limitation, the attorney-client privilege or work product immunity; further, all information transmitted between Plaintiff&#146;s Counsel and
Defendants&#146; Counsel in connection with the Settlement shall be kept confidential and shall be inadmissible in any proceeding in any U.S. federal or state court or other tribunal or otherwise, in accordance with Rule 408 of the Federal Rules of
Evidence as if such Rule applied in all respects in any such proceeding or forum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">57. The Parties intend that the Court retain
jurisdiction for the purpose of effectuating and enforcing the terms of the Settlement and to consider any matters or disputes arising out of or relating to the Settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">58. Without further order of the Court, the Settling Parties may agree to the reasonable extensions of time to carry out any of provisions in
this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">59. Any notice required by this Stipulation shall be submitted by email to each of the signatories below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">60. This Stipulation may be executed in one or more counterparts, each of which constitutes an original, including by signature transmitted via
facsimile or by email. All executed counterparts and each of them shall be deemed to be one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">61. Each counsel or
other person executing this Stipulation or its exhibits on behalf of any Party hereby warrants that such person has full authority to do so. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">62. Plaintiff represents and warrants that he is a Current Walgreens Stockholder and has not assigned any of the Released Claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 27 of
59 PageID #: 269 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Stipulation to be executed, by their
duly authorized attorneys, as of July&nbsp;9, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July 9, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ROBBINS LLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Stephen J. Oddo </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen J. Oddo</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian J. Robbins</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eric M. Carrino</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5060 Shoreham Place, Suite 300</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA
92122</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telephone: (619) <FONT STYLE="white-space:nowrap">525-3990</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (619) 525-3991</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-4.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&#8194;&#8201;&#8201;brobbins@robbinsllp.com</FONT><BR>soddo@robbinsllp.com<BR>ecarrino@robbinsllp.com
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>COOCH AND TAYLOR, P.A.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Blake A. Bennett (#5133)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Nemours
Building</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1007 N. Orange Street, Suite 1120</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wilmington, DE 19801</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (302) 984-3800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (302) 984-3939</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> bbennett@coochtaylor.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Attorneys for Plaintiff</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 28 of
59 PageID #: 270 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July 9, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ABRAMS&nbsp;&amp; BAYLISS LLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ A. Thompson Bayliss</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. Thompson Bayliss (#4379)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christopher
Fitzpatrick Cannataro (#6621)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">20 Montchanin Road</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Suite 200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wilmington, DE 19807</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (302) 778-1033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (302) <FONT STYLE="white-space:nowrap">261-0292</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bayliss@AbramsBayliss.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ROPES&nbsp;&amp; GRAY LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Martin J. Crisp (admitted <I>pro hac vice</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1211 Avenue of the Americas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10036-8704</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (212) 596-9000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) 596-9090</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> Martin.Crisp@ropesgray.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert G. Jones, Esq. (admitted <I>pro hac vice</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Prudential Tower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">800 Boylston Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02199-3600</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (617) 951-7000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (617) 951-7050</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> Robert.Jones@ropesgray.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Attorneys for Defendants James A. Skinner, Stefano Pessina, William C. Foote, Nancy M. Schlichting, Ginger L. Graham, David J. Brailer, Janice M. Babiak, Dominic P. Murphy, John A. Lederer, Jos&eacute; E. Almeida, George R.
Fairweather, and Leonard D. Schaeffer, and Nominal Defendant Walgreens Boots Alliance, Inc.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 29 of
59 PageID #: 271 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 30 of
59 PageID #: 272 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Plaintiff,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">v.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, JANICE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. ALMEIDA,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Defendants,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">-and-</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nominal Defendant.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE GOVERNANCE REFORMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No later than 90 days after the Effective Date,<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> and except as provided in Paragraph 21
of the Stipulation, the Company or Board shall take such actions as necessary to adopt, implement, and/or initiate, as appropriate, the following Corporate Governance Reforms, which shall remain in effect for no less than 5 years unless otherwise
specified below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Walgreens acknowledges and agrees that the filing, pendency, and settlement of the Derivative Action was the primary
factor in the Company&#146;s decision to adopt and implement the Corporate Governance Reforms. Walgreens also acknowledges and agrees that the Corporate Governance Reforms confer substantial benefits to Walgreens and Walgreens&#146; stockholders.
</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specified, all defined terms shall have the same meaning as in the Stipulation and Agreement
of Settlement to which these Corporate Governance Reforms serve as an Exhibit. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 31 of
59 PageID #: 273 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CORPORATE GOVERNANCE REFORMS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>BOARD OF DIRECTORS</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <U>Mandatory Attendance of Directors at Annual Stockholder Meetings</U>. The Company shall revise its Corporate Governance Guidelines to
provide that, absent extenuating circumstances, its Chief Executive Officer and each member of the Board shall attend each annual stockholder meeting either in person or remotely. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Director Training and Continuing Education</U>. Section II of Exhibit A to the Settlement Stipulation entered into in connection with the
settlement of the action captioned <I>Cutler</I> <I>v. Wasson, et al.</I>, Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:14-cv-10408</FONT></FONT> (N.D. Ill.), contemplates that the Company&#146;s directors and senior
officers will receive training on &#147;disclosure-related laws, regulations, policies, and procedures&#148; in years one, three, and five of the implementation period of that settlement. Pursuant to the settlement of this Action, the Company will
cause those same directors and senior officers to receive that training on an annual basis (instead of the semi-annual basis contemplated by the settlement of the <I>Cutler </I>action), and extend the implementation period of this settlement term
(both for purposes of this action and the <I>Cutler </I>action) from five to six years such that those directors and senior officers will receive annual training of the type described above for each year between 2024 and 2029. This training shall be
virtual. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>AUDIT COMMITTEE</B>. The Company shall revise the Audit Committee Charter to include the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <U>Purpose</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall assist the Board in its oversight over the soundness of the Company&#146;s systems of
internal accounting, financial controls, and disclosure controls. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Composition</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least half of the members of the Audit Committee must qualify as an &#147;audit committee financial
expert&#148; as defined by the U.S. Securities and Exchange Commission (&#147;SEC&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <U>Specific Duties</U>:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall review and discuss with management and the Company&#146;s independent auditor on an
annual basis a plan to assess the adequacy and effectiveness of the Company&#146;s systems of internal accounting and financial controls, as well as any related impact on the Company&#146;s disclosure controls and procedures. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Audit Committee&#146;s periodic review of the adequacy and effectiveness of the Company&#146;s
disclosure controls and procedures, as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 32 of
59 PageID #: 274 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
provided by Specific Duty #16 in the current Audit Committee Charter, the Audit Committee shall meet periodically with either the Senior Officers, as defined in the Disclosure Committee Charter,
or a representative of the Disclosure Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures that the Disclosure Committee conducts prior to the filing of each of
the Company&#146;s annual and quarterly Exchange Act reports pursuant to the Disclosure Committee Charter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Committee Reports, as provided by Specific Duty #20 in the current Audit Committee Charter, the
Chair of the Audit Committee shall periodically review with the Board any issues that arise with the quality or integrity of the Company&#146;s disclosure controls and policies, including any significant deficiencies or material weaknesses.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>DISCLOSURE COMMITTEE</B>. The Company shall revise the Disclosure Committee Charter to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either the Senior Officers, as defined in the Disclosure Committee Charter, or a representative of the
Disclosure Committee shall meet periodically, and in no event less than quarterly, with the Audit Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the Company is considering a potential merger, acquisition, or divestiture, the Disclosure Committee
shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluate material written disclosures filed with the SEC regarding any potential strategic transaction,
including potential mergers, acquisitions, divestitures, joint ventures, or reorganizations, prior to public disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meet as needed with pertinent senior management to discuss SEC disclosure obligations regarding any potential
merger, acquisition, or divestiture that the Company believes in good faith must be disclosed in its SEC filings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<B>WHISTLEBLOWER CONTROLS</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall amend its relevant whistleblower policies as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A log of whistleblower complaints regarding the Company&#146;s accounting practices, financial reporting, and
SEC disclosure and compliance obligations made either (i)&nbsp;internally by a Company employee through appropriate reporting channels, including, for example, through the Compliance and Ethics Hotline; or (ii)&nbsp;by an external party such as a
relator through a regulator, governmental authority, or pursuant to a qui </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 33 of
59 PageID #: 275 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
tam complaint (the &#147;Whistleblower Complaints&#148;), as well as the results of all investigations of such Whistleblower Complaints, shall be maintained internally by, or maintained
externally by relevant third-party vendors with oversight from, the Global Chief Compliance and Ethics Officer (or the Vice President, Global Internal Audit, if necessary) for a period of not less than ten (10)&nbsp;years. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At or before each regularly scheduled Audit Committee meeting, the Audit Committee shall be provided with a
written summary of Whistleblower Complaints received by the Company that pertinent senior management considers to be material, as well as any information that pertinent senior management considers material resulting from any internal investigation
into such Whistleblower Complaints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To more explicitly reflect that the Company considers it the duty of all employees to promptly report
compliance concerns to company leaders, Employee Relations, and the Compliance Office, and to more explicitly reflect that they should report such concerns without fear of reprisal or retribution of any kind. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 34 of
59 PageID #: 276 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 1 of 12
PageID #: 308 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Plaintiff,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">v.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, JANICE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. ALMEIDA,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Defendants,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">-and-</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Nominal Defendant.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTION </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>TO:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL OWNERS OF THE COMMON STOCK OF WALGREENS BOOTS ALLIANCE, INC. (&#147;WALGREENS&#148; OR THE
&#147;COMPANY&#148;) CURRENTLY AND AS OF JULY&nbsp;9, 2024 (&#147;WALGREENS STOCKHOLDERS&#148;): </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTICE
RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A WALGREENS STOCKHOLDER, THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT YOUR RIGHTS. IF THE
COURT APPROVES THE SETTLEMENT, YOU WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND FROM PURSUING THE &#147;RELEASED CLAIMS,&#148; AS DEFINED IN THE STIPULATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOU ARE HEREBY NOTIFIED</B>, pursuant to an Order of the U.S. District Court for the District of Delaware (the &#147;Court&#148;), that a
proposed settlement has been reached by the parties to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 2 of 12
PageID #: 309 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the above-captioned stockholder derivative action brought on behalf and for the benefit of Walgreens (the &#147;Derivative Action&#148;).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As explained below, a hearing will be held on January&nbsp;23, 2025, at 1:00 p.m., before the Honorable Gregory B. Williams, at the U.S.
District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801 (the &#147;Settlement Hearing&#148;), at which the Court will determine whether to approve the Settlement. You
have an opportunity to be heard at this hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the settlement are set forth in the Stipulation and summarized in this
Notice. If approved by the Court, the Settlement will fully resolve the Released Claims, including the dismissal of the Derivative Action with prejudice. For a more detailed statement of the matters involved in the Derivative Action, the Settlement,
and the terms discussed in this Notice, the Stipulation may be inspected at the Clerk of Court&#146;s office, U.S. District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE
19801. The Stipulation is also available for viewing on the website of Walgreens at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information. For a fee, all papers filed in the Derivative Action
are available at www.pacer.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice is not intended to be an expression of any opinion by the Court with respect to the merits of
the claims made in the Derivative Action, but is merely to advise you of the pendency and settlement of the Derivative Action. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms herein have the same meanings as set forth Parties&#146; Stipulation and Agreement of
Settlement dated July 9, 2024 (the &#147;Stipulation&#148;), which is available for viewing on the website of Walgreens at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 3 of 12
PageID #: 310 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THERE IS NO CLAIMS PROCEDURE. </B>This case was brought to protect the interests of
Walgreens. The Settlement will result in changes to the Company&#146;s corporate governance, not in payment to individuals, and accordingly, there will be no claims procedure. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE DERIVATIVE ACTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Derivative Action is brought by Plaintiff solely on behalf of and for the benefit of Walgreens and against the Individual Defendants. The
derivative claims arise from the Individual Defendants&#146; alleged breaches of fiduciary duties for, among other things, alleged false and misleading statements regarding a proposed merger between Walgreens and Rite Aid Corporation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PLAINTIFFS&#146; CLAIMS AND THE BENEFITS OF SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff believes that the claims asserted in the Derivative Action are meritorious, and Plaintiff&#146;s entry into this Stipulation and
Settlement is not intended to be and shall not be construed as an admission or concession concerning the relative strength or merit of the claims alleged in the Derivative Action. However, Plaintiff&#146;s Counsel recognizes and acknowledges the
expense and length of continued proceedings necessary to prosecute the Derivative Action against Defendants through trial and possible appeals. Plaintiff also has considered the uncertain outcome and the risk of any litigation, especially in complex
actions such as the Derivative Action, and the difficulties and delays inherent in such litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff&#146;s Counsel have
conducted an investigation and analysis regarding the relevant facts, allegations, defenses, and controlling legal principles, including, <I>inter alia</I>: (i)&nbsp;reviewing Walgreens&#146; internal books and records regarding the alleged
wrongdoing, which were produced in connection with the Section&nbsp;220 Demand; (ii)&nbsp;reviewing Walgreens&#146; press releases, public statements, U.S. Securities and Exchange Commission (&#147;SEC&#148;) filings, and securities analysts&#146;
reports and advisories about the Company, Rite Aid, and the Rite Aid Merger; (iii)&nbsp;reviewing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 4 of 12
PageID #: 311 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related media reports about the Company, Rite Aid, and the Rite Aid Merger; (iv)&nbsp;researching applicable law with respect to the claims alleged in the Derivative Action and potential defenses
thereto; (v)&nbsp;preparing and filing the derivative complaint; and (vi)&nbsp;conducting damages analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on Plaintiff&#146;s
Counsel&#146;s thorough review and analysis of the relevant facts, allegations, defenses, and controlling legal principles, Plaintiff believes that the Settlement set forth in the Stipulation is fair, reasonable, and adequate, and confers
substantial benefits upon Walgreens. Based upon Plaintiff&#146;s Counsel&#146;s evaluation, Plaintiff has determined that the Settlement is in the best interests of Plaintiff, Walgreens, and Current Walgreens Stockholders, and has therefore agreed
to settle the Derivative Action upon the terms and subject to the conditions set forth in the Stipulation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFENDANTS&#146; DENIALS OF WRONGDOING AND LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants have denied and continue to deny any and all fault, wrongdoing, and liability for the claims and damages asserted, or that could
have been asserted, in the Derivative Action and believe that their defenses to these claims are meritorious. Had the terms of this Stipulation not been reached, Defendants would have continued to contest Plaintiff&#146;s allegations vigorously, and
Defendants maintain that they had and have meritorious defenses to all claims alleged in the Derivative Action. However, Defendants recognize and acknowledge the expense and length of continued proceedings necessary to defend against the claims
asserted in the Derivative Action through trial and possible appeals. Defendants also have considered the uncertain outcome and the risk of any litigation, especially in complex actions such as the Derivative Action, and the difficulties and delays
inherent in such litigation. Accordingly, and without admitting the validity of any of the claims that Plaintiff has asserted in the Derivative Action or any liability with respect thereto, Defendants believe that the Settlement set forth in the
Stipulation is fair, reasonable, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 5 of 12
PageID #: 312 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adequate, and in the best interests of Walgreens and Current Walgreens Stockholders. Neither this Stipulation, nor any of its terms or provisions, nor entry of the Judgment, nor any document or
exhibit referred or attached to the Stipulation, nor any action taken to effect the Stipulation, is, may be construed as, or may be used as evidence of the validity of any of the Released Claims or any admission by or against any of the Defendants
of any fault, wrongdoing, or concession of liability, or any infirmity in the defenses that could have been asserted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS OF THE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the proposed Settlement are set forth in the Stipulation, which has been filed with the Court and is available for
viewing on Walgreens&#146; website at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement -information. The following is only a summary of its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Settlement, Walgreens has agreed to implement and maintain the corporate governance reforms set forth in Exhibit A to
the Stipulation (&#147;Corporate Governance Reforms&#148;). The Corporate Governance Reforms shall be maintained by Walgreens for a period of not less than five (5)&nbsp;years. Walgreens and the Board acknowledge that the filing and prosecution of
the Derivative Action caused the Company&#146;s decision to adopt and implement the Corporate Governance Reforms. Walgreens and the Board also acknowledge and agree that the Corporate Governance Reforms confer a substantial benefit to Walgreens and
Current Walgreens Stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporate Governance Reforms require: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>BOARD OF DIRECTORS</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A.
<U>Mandatory Attendance of Directors at Annual Stockholder Meetings</U>. The Company shall revise its Corporate Governance Guidelines to provide that, absent extenuating circumstances, its Chief Executive Officer and each member of the Board shall
attend each annual stockholder meeting either in person or remotely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 6 of 12
PageID #: 313 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Director Training and Continuing Education</U>. Section II of Exhibit A to the
Settlement Stipulation entered into in connection with the settlement of the action captioned <I>Cutler</I> <I>v. Wasson, et al.</I>, Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:14-cv-10408</FONT></FONT> (N.D. Ill.),
contemplates that the Company&#146;s directors and senior officers will receive training on &#147;disclosure-related laws, regulations, policies, and procedures&#148; in years one, three, and five of the implementation period of that settlement.
Pursuant to the settlement of this Action, the Company will cause those same directors and senior officers to receive that training on an annual basis (instead of the semi-annual basis contemplated by the settlement of the <I>Cutler </I>action), and
extend the implementation period of this settlement term (both for purposes of this action and the <I>Cutler </I>action) from five to six years such that those directors and senior officers will receive annual training of the type described above
for each year between 2024 and 2029. This training shall be virtual. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>AUDIT COMMITTEE</B>. The Company shall revise the Audit
Committee Charter to include the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <U>Purpose</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall assist the Board in its oversight over the soundness of the Company&#146;s systems of
internal accounting, financial controls, and disclosure controls. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Composition</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least half of the members of the Audit Committee must qualify as an &#147;audit committee financial
expert&#148; as defined by the U.S. Securities and Exchange Commission (&#147;SEC&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <U>Specific Duties</U>:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall review and discuss with management and the Company&#146;s independent auditor on an
annual basis a plan to assess the adequacy and effectiveness of the Company&#146;s systems of internal accounting and financial controls, as well as any related impact on the Company&#146;s disclosure controls and procedures. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Audit Committee&#146;s periodic review of the adequacy and effectiveness of the Company&#146;s
disclosure controls and procedures, as provided by Specific Duty #16 in the current Audit Committee Charter, the Audit Committee shall meet periodically with either the Senior Officers, as defined in the Disclosure Committee Charter, or a
representative of the Disclosure Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures that the Disclosure Committee conducts prior to the filing of each of the
Company&#146;s annual and quarterly Exchange Act reports pursuant to the Disclosure Committee Charter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 7 of 12
PageID #: 314 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Committee Reports, as provided by Specific Duty #20 in the current Audit Committee Charter, the
Chair of the Audit Committee shall periodically review with the Board any issues that arise with the quality or integrity of the Company&#146;s disclosure controls and policies, including any significant deficiencies or material weaknesses.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>DISCLOSURE COMMITTEE</B>. The Company shall revise the Disclosure Committee Charter to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either the Senior Officers, as defined in the Disclosure Committee Charter, or a representative of the
Disclosure Committee shall meet periodically, and in no event less than quarterly, with the Audit Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the Company is considering a potential merger, acquisition, or divestiture, the Disclosure Committee
shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluate material written disclosures filed with the SEC regarding any potential strategic transaction,
including potential mergers, acquisitions, divestitures, joint ventures, or reorganizations, prior to public disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meet as needed with pertinent senior management to discuss SEC disclosure obligations regarding any potential
merger, acquisition, or divestiture that the Company believes in good faith must be disclosed in its SEC filings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<B>WHISTLEBLOWER CONTROLS</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall amend its relevant whistleblower policies as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A log of whistleblower complaints regarding the Company&#146;s accounting practices, financial reporting, and
SEC disclosure and compliance obligations made either (i)&nbsp;internally by a Company employee through appropriate reporting channels, including, for example, through the Compliance and Ethics Hotline; or (ii)&nbsp;by an external party such as a
relator through a regulator, governmental authority, or pursuant to a qui tam complaint (the &#147;Whistleblower Complaints&#148;), as well as the results of all investigations of such Whistleblower Complaints, shall be maintained internally by, or
maintained externally by relevant third-party vendors with oversight from, the Global Chief Compliance and Ethics Officer (or the Vice President, Global Internal Audit, if necessary) for a period of not less than ten (10)&nbsp;years.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At or before each regularly scheduled Audit Committee meeting, the Audit Committee shall be provided with a
written summary of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 8 of 12
PageID #: 315 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Whistleblower Complaints received by the Company that pertinent senior management considers to be material, as well as any information that pertinent senior management considers material
resulting from any internal investigation into such Whistleblower Complaints. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To more explicitly reflect that the Company considers it the duty of all employees to promptly report
compliance concerns to company leaders, Employee Relations, and the Compliance Office, and to more explicitly reflect that they should report such concerns without fear of reprisal or retribution of any kind. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISMISSAL AND RELEASES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Settlement is conditioned upon the occurrence of certain events, which include, among other things: (i)&nbsp;final approval of the
Settlement by the Court following notice to Current Walgreens Stockholders and the Settlement Hearing contemplated by the Stipulation; and (ii)&nbsp;Court entry of the Judgment, approving the Settlement and dismissing with prejudice the Derivative
Action, without awarding costs to any Party, except as provided herein (the &#147;Effective Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Effective Date,
Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged the Released Claims against the Released
Parties and their Related Persons. Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of the Judgment shall have, covenanted not to sue any Released Party or any of their Related Persons
with respect to any Released Claims, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting the Released Claims against any Released Party or any of their Related Persons or Defendants&#146; Counsel except to
enforce the releases and other terms and conditions contained in the Stipulation and/or the Judgment entered pursuant thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 9 of 12
PageID #: 316 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Effective Date, each of Walgreens and the Individual Defendants shall be deemed to
have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged each and all of Plaintiff and Plaintiff&#146;s Counsel from the Released Defendants&#146; Claims. Walgreens and the Individual
Defendants shall be deemed to have, and by operation of the Judgment shall have, covenanted not to sue Plaintiff or Plaintiff&#146;s Counsel with respect to any Released Defendants&#146; Claims, and shall be permanently barred and enjoined from
instituting, commencing, or prosecuting Released Defendants&#146; Claims against Plaintiff or Plaintiff&#146;s Counsel except to enforce the releases and other terms and conditions contained in the Stipulation and/or the Judgment entered pursuant
thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VI.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PLAINTIFFS&#146; ATTORNEYS&#146; FEES AND EXPENSES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After negotiating the substantive terms of the settlement, Plaintiff&#146;s Counsel and Defendants&#146; Counsel separately negotiated the
amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel in recognition of the benefit provided to Walgreens and Current Walgreens Stockholders due to the Corporate Governance Reforms. The Parties have agreed that
Plaintiff&#146;s Counsel shall apply to the Court for the Fee and Expense Amount in the total amount of $750,000, which shall be Plaintiff&#146;s Counsel&#146;s sole application for an award of fees and expenses in connection with the Derivative
Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Plaintiff&#146;s Counsel have neither received any payment for their services in conducting the Derivative Action, nor
have counsel been reimbursed for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred. The Parties believe that the sum agreed to is within the range of attorneys&#146; fees and
expenses approved by courts under similar circumstances in litigation of this type. Walgreens stockholders are not personally liable for the payment of any award of attorneys&#146; fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 10 of 12
PageID #: 317 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff&#146;s Counsel may apply to the Court for a service award of up to $2,500 for
Plaintiff, only to be paid upon Court approval, and to be paid from the Fee and Expense Amount in recognition of Plaintiff&#146;s participation and effort in the prosecution of the Derivative Action. Neither Walgreens nor any of the Individual
Defendants shall be liable for any portion of the service award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Settlement Hearing will be held before the Honorable Gregory B. Williams, at the U.S. District Court for the District of Delaware, J. Caleb
Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801 (the &#147;Settlement Hearing&#148;), at which the Court will determine: (i)&nbsp;whether the terms of the Stipulation should be approved as fair, reasonable, and
adequate; (ii)&nbsp;whether the Notice fully satisfied the requirements of Rule 23.1 of the Federal Rule of Civil Procedure and the requirements of due process; (iii)&nbsp;whether all Released Claims against the Released Parties should be fully and
finally released; (iv)&nbsp;whether the <FONT STYLE="white-space:nowrap">agreed-to</FONT> Fee and Expense Amount should be approved; and (v)&nbsp;such other matters as the Court may deem appropriate. The Settlement Hearing may be continued by the
Court at the Settlement Hearing, or at any adjourned session thereof without further notice. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VIII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE RIGHT TO OBJECT AND/OR BE HEARD AT THE HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Walgreens Stockholder may object and/or appear and show cause, if he, she, or it has any concern why the Settlement should not be approved
as fair, reasonable, and adequate, or why the Judgment should not be entered thereon, or why the <FONT STYLE="white-space:nowrap">agreed-to</FONT> Fee and Expense Amount should not be approved. However, unless otherwise ordered by the Court, you
shall only be heard or entitled to contest the approval of the terms and conditions of the Settlement, or, if approved, the Judgment to be entered thereon approving the same, or the amount of attorneys&#146; fees and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 11 of 12
PageID #: 318 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement of expenses to Plaintiff&#146;s Counsel, unless you have, <B><I>at least fourteen (14)</I></B><B><I></I></B><B><I>&nbsp;calendar days prior to the Settlement Hearing</I></B>, filed
with the Court a written notice of objection containing the following information: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Your name, legal address, and telephone number; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The case name and number (<I>Clem v. Skinner, et al.</I>, Case No. <FONT STYLE="white-space:nowrap">1:21-cv-00406);</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Proof of being a Walgreens stockholder currently and as of July 9, 2024; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The date(s) you acquired your Walgreens shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. A statement of each of each objection being made; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Notice of whether you intend to appear at the Settlement Hearing (you are not required to appear); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Copies of any papers you intend to submit to the Court, along with the names of any witness(es) you intend to call to testify at the
Settlement Hearing and the subject(s) of their testimony. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOUR WRITTEN OBJECTIONS MUST BE POSTMARKED OR ON FILE WITH THE CLERK OF THE
COURT NO LATER THAN JANUARY 9, 2025. Only stockholders who have filed and delivered valid and timely written notices of objection will be entitled to be heard at the Settlement Hearing unless the Court orders otherwise. All written objections and
supporting papers must be filed with the Clerk of the Court, U.S. District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801, and serve such materials by that date, to
each of the following Settling Parties&#146; counsel: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiffs:</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>COOCH AND TAYOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: Blake A. Bennett</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">The Brandywine Building</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1000 N. West Street, Suite 1500</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19801</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Telephone: (302) 984-3800</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Counsel for Defendants:</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>ABRAMS&nbsp;&amp; BAYLISS LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: A. Thompson Bayliss</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">20 Montchanin Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Suite
200</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19807</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Telephone: (302) 778-1033</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48 &#8195;Filed 11/22/24 &#8195;Page 12 of 12
PageID #: 319 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>bbennett@coochtaylor.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>Bayliss@AbramsBayliss.com</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>ROBBINS LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: Stephen J. Oddo</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5060 Shoreham Place, Suite 300</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">San Diego, CA 92122</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Telephone: (619) <FONT STYLE="white-space:nowrap">525-3990</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>soddo@robbinsllp.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>ROPES&nbsp;&amp; GRAY LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: Martin J. Crisp</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1211 Avenue of the Americas</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10036-8704</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Telephone: (212) 596-9000</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>Martin.Crisp@ropesgray.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise ordered by the Court, any Current Walgreens Stockholder who does not make his, her, or its
objection in the manner provided herein shall be deemed to have waived such objection and shall forever be barred and foreclosed from making any objection to the fairness, reasonableness, or adequacy of the Settlement, or to otherwise be heard, and
shall otherwise be bound by the Judgment to be entered and the releases to be given. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IX.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXAMINATION OF PAPERS AND INQUIRIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is additional information concerning the Settlement available in the Stipulation, which is available for viewing on Walgreens&#146;
website at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information. You may also inspect the Stipulation during business hours at the office of the Clerk of the Court, U.S. District Court for the
District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801. Or you can call Robbins LLP, Stephen J. Oddo, telephone: (619) <FONT STYLE="white-space:nowrap">525-</FONT> 3990, for additional
information concerning the settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE DO NOT CONTACT THE COURT OR WALGREENS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGARDING THIS NOTICE. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATED:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">BY ORDER OF THE COURT UNITED STATES</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">DISTRICT COURT OF THE DISTRICT OF DELAWARE</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 47 of
59 PageID #: 289 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT C </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 1 of 6
PageID #: 320 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, JANICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. ALMEIDA,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">-and-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[PROPOSED] REVISED PRELIMINARY APPROVAL ORDER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This matter came before the Court for a hearing on November 19, 2024. Plaintiff has made an unopposed motion, pursuant to Rule 23.1 of the
Federal Rules of Civil Procedure, for an order: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) preliminarily approving the proposed settlement (&#147;Settlement&#148;) of stockholder derivative
claims, in accordance with the Stipulation and Agreement of Settlement dated July&nbsp;9, 2024 (the &#147;Stipulation&#148;); and (ii)&nbsp;approving the form and manner of the Notice of the
Settlement.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Stipulation sets forth the terms and conditions for the
Settlement, including, but not limited to, a proposed Settlement and dismissal of the above-captioned Derivative Action; </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise expressly provided below or as the context otherwise requires, all capitalized terms
contained herein shall have the same meanings and/or definitions as set forth in the Stipulation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 2 of 6
PageID #: 321 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Court having: (i)&nbsp;read and considered Plaintiff&#146;s Unopposed Motion for
Preliminary Approval of Settlement together with the accompanying Memorandum of Points and Authorities; (ii)&nbsp;read and considered the Stipulation, as well as all the exhibits attached thereto, including the Notice of Pendency and Proposed
Settlement of Stockholder Derivative Action (the &#147;Notice&#148;); and (iii)&nbsp;heard and considered arguments by counsel for the Parties in favor of preliminary approval of the Settlement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Court finds, upon a preliminary evaluation, that the proposed Settlement falls within the range of possible approval criteria, as
it provides a beneficial result for Walgreens and appears to be the product of serious, informed, <FONT STYLE="white-space:nowrap">non-collusive</FONT> settlement negotiations among the Parties; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Court also finds, upon a preliminary evaluation, that Walgreens stockholders should be apprised of the Settlement through the
proposed form of notice, allowed to file objections, if any, thereto, and appear at the Settlement Hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IT IS HEREBY
ORDERED, ADJUDGED, AND DECREED AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. This Court, for purposes of this Preliminary Approval Order, adopts the definitions set
forth in the Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Court preliminarily approves, subject to further consideration at the Settlement Hearing described
below, the Settlement as set forth in the Stipulation as being fair, reasonable, and adequate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. A hearing shall be held on
January&nbsp;23, 2025, at 1:00 p.m., before the Honorable Gregory B. Williams, at the U.S. District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801 (the
&#147;Settlement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 3 of 6
PageID #: 322 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Hearing&#148;), at which the Court will determine: (i)&nbsp;whether the terms of the Stipulation should be approved as fair, reasonable, and adequate; (ii)&nbsp;whether the Notice fully satisfied
the requirements of Rule 23.1 of the Federal Rule of Civil Procedure and the requirements of due process; (iii)&nbsp;whether all Released Claims against the Released Parties should be fully and finally released; (iv)&nbsp;whether the <FONT
STYLE="white-space:nowrap">agreed-to</FONT> Fee and Expense Amount should be approved; and (v)&nbsp;such other matters as the Court may deem appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Court finds that the form, substance, and dissemination of information regarding the proposed Settlement in the manner set out in this
Preliminary Approval Order constitutes the best notice practicable under the circumstances and complies fully with Rule 23.1 of the Federal Rules of Civil Procedure and due process. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Within fourteen (14)&nbsp;calendar days after the entry of this Preliminary Approval Order, Walgreens shall cause the Summary Notice to be
published one time in <I>Business Wire</I>, cause the Stipulation and the Notice to be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished to the SEC, and Walgreens shall post a link to the Stipulation and the Notice on the
&#147;Investor Relations&#148; page of Walgreens&#146; website, and shall maintain that link through the date of the Settlement Hearing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. All costs incurred in the filing and publication of the Notice shall be paid by Walgreens, and Walgreens shall undertake all administrative
responsibility for the filing and publication of the Notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. At least <FONT STYLE="white-space:nowrap">twenty-one</FONT>
(21)&nbsp;calendar days after the entry of this Preliminary Approval Order, Defendants&#146; Counsel shall file with the Court an appropriate affidavit or declaration with respect to filing, publishing, and posting the Notice as provided for in
paragraph 5 of this Preliminary Approval Order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 4 of 6
PageID #: 323 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. All Current Walgreens Stockholders shall be subject to and bound by the provisions of the
Stipulation and the releases contained therein, and by all orders, determinations, and judgments in the Derivative Action concerning the Settlement, whether favorable or unfavorable to Current Walgreens Stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Pending final determination of whether the Settlement should be approved, Plaintiff and Current Walgreens Stockholders shall not commence or
prosecute against any of the Released Parties any action or proceeding in any court or tribunal asserting any of the Released Claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.
Any stockholder of Walgreens common stock may appear and show cause, if he, she, or they have any reason why the Settlement embodied in the Stipulation should not be approved as fair, reasonable, and adequate, or why a judgment should or should not
be entered hereon, or the Fee and Expense Amount or service award should not be awarded. However, no Walgreens stockholder shall be heard or entitled to contest the approval of the proposed Settlement, or, if approved, the Judgment to be entered
hereon, unless that Walgreens stockholder has caused to be filed, and served on counsel as noted below, written objections containing the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The stockholders&#146; name, legal address, and telephone number; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The case name and number (<I>Clem v. Skinner, et al.</I>, Case No.
<FONT STYLE="white-space:nowrap">1:21-cv-00406);</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proof of being a Walgreens stockholder currently and as of July 9, 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date(s) the stockholder acquired Walgreens shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A statement of each of each objection being made; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of whether the stockholder intends to appear at the Settlement Hearing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Copies of any papers the stockholder intends to submit to the Court, along with the names of any witness(es)
the stockholder intends to call to testify at the Settlement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 5 of 6
PageID #: 324 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Hearing and the subject(s) of their testimony. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. At least fourteen
(14)&nbsp;calendar days prior to the Settlement Hearing set for January&nbsp;23, 2025, any such person must file the written objection(s) and corresponding materials with the Clerk of the Court, U.S. District Court for the District of Delaware, J.
Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801, and serve such materials by that date, to each of the following Parties&#146; counsel: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff:</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COOCH AND TAYOR</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Blake A. Bennett</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Brandywine Building</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1000 N. West Street, Suite 1500</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19801</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (302) 984-3800</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> bbennett@coochtaylor.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Defendants:</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABRAMS&nbsp;&amp; BAYLISS LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: A. Thompson
Bayliss</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 Montchanin Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 200</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19807</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (302) <FONT
STYLE="white-space:nowrap">778-1033</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bayliss@AbramsBayliss.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ROBBINS LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Stephen J. Oddo</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5060 Shoreham Place, Suite 300</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92122</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (619) <FONT STYLE="white-space:nowrap">525-3990</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> soddo@robbinsllp.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ROPES&nbsp;&amp; GRAY LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Martin
J. Crisp</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1211 Avenue of the Americas</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
10036-8704</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (212) 596-9000</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> Martin.Crisp@ropesgray.com</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Only stockholders who have filed with the Court and sent to the Parties&#146; counsel valid and
timely written notices of objection will be entitled to be heard at the hearing unless the Court orders otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. Any Person or
entity who fails to appear or object in the manner provided herein shall be deemed to have waived such objection and shall forever be foreclosed from making any objection to the fairness, reasonableness, or adequacy of the Settlement and to the Fee
and Expense Amount, unless otherwise ordered by the Court, and shall be forever bound by the Judgment to be entered and the releases to be given as set forth in the Stipulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. Plaintiff shall file his motion for final approval of the Settlement at least twenty-eight (28)&nbsp;calendar days prior to the Settlement
Hearing. If there is any objection to the Settlement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 48-1 &#8195;Filed 11/22/24 &#8195;Page 6 of 6
PageID #: 325 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff shall file a response to the objection(s) at least seven (7)&nbsp;calendar days
prior to the Settlement Hearing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. All proceedings in the Derivative Action are stayed until further order of the Court, except as may
be necessary to implement the Settlement or comply with the terms of this Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. This Court may, for good cause, extend any of
the deadlines set forth in this Preliminary Approval Order without further notice to Walgreens stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. Neither the Stipulation
nor the Settlement, nor any act performed or document executed pursuant to or in furtherance of the Stipulation or the Settlement: (i)&nbsp;is or may be deemed to be or may be offered, attempted to be offered or used in any way by the Parties or any
other Person as a presumption, a concession or an admission of, or evidence of, any fault, wrongdoing or liability of the Parties or Released Parties, or of the validity of any Released Claims; or (ii)&nbsp;is intended by the Parties to be offered
or received as evidence or used by any other person in any other actions or proceedings, whether civil, criminal, or administrative, other than to enforce the terms therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. The Court reserves: (i)&nbsp;the right to approve the Settlement, with such modifications as may be agreed to by counsel for the Parties
consistent with such Settlement, without further notice to Walgreens stockholders; and (ii)&nbsp;the right to continue or adjourn the Settlement Hearing from time to time or by oral announcement at the hearing or at any adjournment thereof, without
further notice to Walgreens stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IT IS SO ORDERED. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DATED:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HONORABLE GREGORY B. WILLIAMS</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UNITED STATES DISTRICT COURT</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 54 of
59 PageID #: 296 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT D </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 55 of
59 PageID #: 297 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, JANICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. ALMEIDA,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">-and-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>[PROPOSED] ORDER AND FINAL JUDGMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This matter came before the Court for hearing on <U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024, to consider approval of the proposed
settlement (&#147;Settlement&#148;) set forth in the Stipulation and Agreement of Settlement dated July 9, 2024, and the exhibits thereto (the &#147;Stipulation&#148;). The Court has reviewed and considered all documents, evidence, objections (if
any), and arguments presented in support of or against the Settlement. Good cause appearing therefore, the Court enters this Judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IT
IS HEREBY ORDERED, ADJUDGED, AND DECREED that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. This Judgment incorporates by reference the definitions in the Stipulation, and all
capitalized terms used herein shall have the same meanings as set forth in the Stipulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 56 of
59 PageID #: 298 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Court has jurisdiction over the subject matter of the Derivative Action, including
all matters necessary to effectuate the Settlement, and over all Parties to the Derivative Action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Court finds that the Notice
provided to Walgreens Boots Alliance, Inc. (&#147;Walgreens&#148;) stockholders constituted the best notice practicable under the circumstances. The Notice fully satisfied the requirements of Rule 23.1 of the Federal Rules of Civil Procedure and the
requirements of due process. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Court hereby approves the Settlement set forth in the Stipulation and finds that the Settlement is, in
all respects, fair, reasonable, and adequate to each of the Parties, and further finds that the Settlement is in the best interests of Walgreens and its stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Derivative Action and all claims contained therein, as well as all of the Released Claims against Released Parties, are dismissed with
prejudice. The Parties are to bear their own costs, except as otherwise provided below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Upon the Effective Date, Walgreens, Plaintiff,
and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of this Judgment shall have, fully, finally, and forever released, relinquished, and discharged the Released Claims against the Released Parties and their
Related Persons. Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of this Judgment shall have, covenanted not to sue any Released Party or any of their Related Persons with respect to any
Released Claims, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting the Released Claims against any Released Party or any of their Related Persons or Defendants&#146; Counsel except to enforce the releases and
other terms and conditions contained in the Stipulation and/or this Judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 57 of
59 PageID #: 299 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Upon the Effective Date, each of Walgreens and the Individual Defendants shall be deemed
to have, and by operation of this Judgment shall have, fully, finally, and forever released, relinquished, and discharged each and all of Plaintiff and Plaintiff&#146;s Counsel from the Released Defendants&#146; Claims. Walgreens and the Individual
Defendants shall be deemed to have, and by operation of this Judgment shall have, covenanted not to sue Plaintiff or Plaintiff&#146;s Counsel with respect to any Released Defendants&#146; Claims, and shall be permanently barred and enjoined from
instituting, commencing, or prosecuting Released Defendants&#146; Claims against Plaintiff or Plaintiff&#146;s Counsel except to enforce the releases and other terms and conditions contained in the Stipulation and/or this Judgment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Nothing herein shall in any way impair or restrict the rights of any Party to enforce the terms of the Stipulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. During the course of the litigation, all parties and their respective counsel at all times complied with the requirements of Rule 11 of the
Federal Rules of Civil Procedure, and all other similar laws or statutes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. The Court hereby approves the sum of $750,000 for the
payment of Plaintiff&#146;s Counsel&#146;s attorneys&#146; fees and expenses in the Derivative Action (&#147;Fee and Expense Amount&#148;), and finds that the Fee and Expense Amount is fair and reasonable. No other fees, costs, or expenses may be
awarded to Plaintiff&#146;s Counsel in connection with the Settlement. The Fee and Expense Amount shall be distributed in accordance with the terms of the Stipulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The Court hereby approves the service awards of $2,500 for Plaintiff, which shall be paid from the Fee and Expense Amount in recognition of
Plaintiff&#146;s participation and effort in the prosecution of the Derivative Action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 58 of
59 PageID #: 300 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Neither the Stipulation nor the Settlement, nor any act performed or document executed
pursuant to or in furtherance of the Stipulation or the Settlement: (i)&nbsp;is or may be deemed to be or may be offered, attempted to be offered, or used in any way by the Parties or any other Person as a presumption, a concession, or an admission
of, or evidence of, any fault, wrongdoing, or liability of the Parties or Released Parties, or of the validity of any Released Claims; or (ii)&nbsp;is intended by the Parties to be offered or received as evidence or used by any other person in any
other actions or proceedings, whether civil, criminal, or administrative, other than to enforce the terms therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. The Released
Parties may file the Stipulation and/or the Judgment, and file or reference acts performed or documents executed pursuant to or in furtherance of the Stipulation and/or the Judgment: (i)&nbsp;in any action that may be brought against them in order
to support a defense or counterclaim based on principles of res judicata, collateral estoppel, full faith and credit, release, good faith settlement, judgment bar or reduction, or any other theory of claim preclusion or issue preclusion or similar
defense or counterclaim; (ii)&nbsp;in furtherance of the Settlement contemplated in the Stipulation; and (iii)&nbsp;in any action to enforce the Settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. Without affecting the finality of this Judgment in any way, this Court hereby retains continuing jurisdiction with respect to
implementation and enforcement of the terms of the Stipulation. If for any reason the Effective Date does not occur, or if the Stipulation is in any way canceled, terminated or fails to become Final in accordance with its terms, then: (i)&nbsp;all
Parties and Released Persons shall be restored to their respective positions in the Derivative Action as of the Execution date of the Stipulation; (ii)&nbsp;all releases delivered in connection with the Stipulation shall be null and void, except as
otherwise provided for in the Stipulation; (iii)&nbsp;the Fee and Expense Amount paid to Plaintiff&#146;s Counsel shall be refunded and returned within twenty (20)&nbsp;calendar days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff">Case 1:21-cv-00406-GBW &#8195;Document 41-1 &#8195;Filed 07/10/24 &#8195;Page 59 of
59 PageID #: 301 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of receiving notice from Defendants or from a court of appropriate jurisdiction; and (iv)&nbsp;all negotiations, proceedings, documents prepared, and statements made in connection herewith shall
be without prejudice to the Parties, shall not be deemed or construed to be an admission by a Party of any act, matter, or proposition, and shall not be used in any manner for any purpose in any subsequent proceeding in the Derivative Action, or in
any other action or proceeding. In such event, the terms and provisions of the Stipulation shall have no further force and effect with respect to the Parties and shall not be used in the Derivative Action or in any other proceeding for any purpose.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Pursuant to Rule 23.1 of the Federal Rules of Civil Procedure, this Court hereby finally approves the Stipulation and Settlement in
all respects, and orders the Parties to perform its terms to the extent the Parties have not already done so. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. This Judgment is a final
judgment, and the Court finds that no just reason exists for delay in entering the Judgment in accordance with the Stipulation. Accordingly, the Clerk is hereby directed to enter this Judgment forthwith in accordance with Rule 58 of the Federal
Rules of Civil Procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IT IS SO ORDERED. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATED:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HONORABLE GREGORY B.
WILLIAMS</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UNITED STATES DISTRICT COURT</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d898694dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 1
 of 12 PageID #: 308 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE DISTRICT OF DELAWARE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES CLEM, Derivatively on Behalf of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:21-cv-00406-GBW</FONT></FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JAMES A. SKINNER, STEFANO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PESSINA, WILLIAM C. FOOTE,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NANCY M. SCHLICHTING, GINGER L.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAHAM, DAVID J. BRAILER, <SUB STYLE="font-size:75%; vertical-align:bottom">JANICE</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">M. BABIAK, DOMINIC P. MURPHY,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JOHN A. LEDERER, JOS&Eacute; E. <SUB STYLE="font-size:75%; vertical-align:bottom">ALMEIDA,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GEORGE R. FAIRWEATHER, and</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LEONARD D. SCHAEFFER,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">-and-</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WALGREENS BOOTS ALLIANCE, INC.<SUB STYLE="font-size:75%; vertical-align:bottom">,</SUB></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a Delaware corporation,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DERIVATIVE ACTION </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>TO:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL OWNERS OF THE COMMON STOCK OF WALGREENS BOOTS ALLIANCE, INC. (&#147;WALGREENS&#148; OR THE
&#147;COMPANY&#148;) CURRENTLY AND AS OF JULY&nbsp;9, 2024 (&#147;WALGREENS STOCKHOLDERS&#148;): </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THIS NOTICE
RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A WALGREENS STOCKHOLDER, THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT YOUR RIGHTS. IF THE
COURT APPROVES THE SETTLEMENT, YOU WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND FROM PURSUING THE &#147;RELEASED CLAIMS,&#148; AS DEFINED IN THE STIPULATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOU ARE HEREBY NOTIFIED</B>, pursuant to an Order of the U.S. District Court for the District of Delaware (the &#147;Court&#148;), that a
proposed settlement has been reached by the parties to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 2
 of 12 PageID #: 309 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the above-captioned stockholder derivative action brought on behalf and for the benefit of Walgreens (the &#147;Derivative Action&#148;).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As explained below, a hearing will be held on January&nbsp;23, 2025, at 1:00 p.m., before the Honorable Gregory B. Williams, at the U.S.
District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801 (the &#147;Settlement Hearing&#148;), at which the Court will determine whether to approve the Settlement. You
have an opportunity to be heard at this hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the settlement are set forth in the Stipulation and summarized in this
Notice. If approved by the Court, the Settlement will fully resolve the Released Claims, including the dismissal of the Derivative Action with prejudice. For a more detailed statement of the matters involved in the Derivative Action, the Settlement,
and the terms discussed in this Notice, the Stipulation may be inspected at the Clerk of Court&#146;s office, U.S. District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE
19801. The Stipulation is also available for viewing on the website of Walgreens at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information. For a fee, all papers filed in the Derivative Action
are available at www.pacer.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice is not intended to be an expression of any opinion by the Court with respect to the merits of
the claims made in the Derivative Action, but is merely to advise you of the pendency and settlement of the Derivative Action. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><A NAME="ex99_2898694_1"></A><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All capitalized terms herein have the same meanings as set forth Parties&#146; Stipulation and Agreement of
Settlement dated July 9, 2024 (the &#147;Stipulation&#148;), which is available for viewing on the website of Walgreens at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 3
 of 12 PageID #: 310 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THERE IS NO CLAIMS PROCEDURE. </B>This case was brought to protect the interests of
Walgreens. The Settlement will result in changes to the Company&#146;s corporate governance, not in payment to individuals, and accordingly, there will be no claims procedure. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE DERIVATIVE ACTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Derivative Action is brought by Plaintiff solely on behalf of and for the benefit of Walgreens and against the Individual Defendants. The
derivative claims arise from the Individual Defendants&#146; alleged breaches of fiduciary duties for, among other things, alleged false and misleading statements regarding a proposed merger between Walgreens and Rite Aid Corporation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PLAINTIFFS&#146; CLAIMS AND THE BENEFITS OF SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff believes that the claims asserted in the Derivative Action are meritorious, and Plaintiff&#146;s entry into this Stipulation and
Settlement is not intended to be and shall not be construed as an admission or concession concerning the relative strength or merit of the claims alleged in the Derivative Action. However, Plaintiff&#146;s Counsel recognizes and acknowledges the
expense and length of continued proceedings necessary to prosecute the Derivative Action against Defendants through trial and possible appeals. Plaintiff also has considered the uncertain outcome and the risk of any litigation, especially in complex
actions such as the Derivative Action, and the difficulties and delays inherent in such litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff&#146;s Counsel have
conducted an investigation and analysis regarding the relevant facts, allegations, defenses, and controlling legal principles, including, <I>inter alia</I>: (i)&nbsp;reviewing Walgreens&#146; internal books and records regarding the alleged
wrongdoing, which were produced in connection with the Section&nbsp;220 Demand; (ii)&nbsp;reviewing Walgreens&#146; press releases, public statements, U.S. Securities and Exchange Commission (&#147;SEC&#148;) filings, and securities analysts&#146;
reports and advisories about the Company, Rite Aid, and the Rite Aid Merger; (iii)&nbsp;reviewing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 4
 of 12 PageID #: 311 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related media reports about the Company, Rite Aid, and the Rite Aid Merger; (iv)&nbsp;researching applicable law with respect to the claims alleged in the Derivative Action and potential defenses
thereto; (v)&nbsp;preparing and filing the derivative complaint; and (vi)&nbsp;conducting damages analyses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on Plaintiff&#146;s
Counsel&#146;s thorough review and analysis of the relevant facts, allegations, defenses, and controlling legal principles, Plaintiff believes that the Settlement set forth in the Stipulation is fair, reasonable, and adequate, and confers
substantial benefits upon Walgreens. Based upon Plaintiff&#146;s Counsel&#146;s evaluation, Plaintiff has determined that the Settlement is in the best interests of Plaintiff, Walgreens, and Current Walgreens Stockholders, and has therefore agreed
to settle the Derivative Action upon the terms and subject to the conditions set forth in the Stipulation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFENDANTS&#146; DENIALS OF WRONGDOING AND LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants have denied and continue to deny any and all fault, wrongdoing, and liability for the claims and damages asserted, or that could
have been asserted, in the Derivative Action and believe that their defenses to these claims are meritorious. Had the terms of this Stipulation not been reached, Defendants would have continued to contest Plaintiff&#146;s allegations vigorously, and
Defendants maintain that they had and have meritorious defenses to all claims alleged in the Derivative Action. However, Defendants recognize and acknowledge the expense and length of continued proceedings necessary to defend against the claims
asserted in the Derivative Action through trial and possible appeals. Defendants also have considered the uncertain outcome and the risk of any litigation, especially in complex actions such as the Derivative Action, and the difficulties and delays
inherent in such litigation. Accordingly, and without admitting the validity of any of the claims that Plaintiff has asserted in the Derivative Action or any liability with respect thereto, Defendants believe that the Settlement set forth in the
Stipulation is fair, reasonable, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 5
 of 12 PageID #: 312 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adequate, and in the best interests of Walgreens and Current Walgreens Stockholders. Neither this Stipulation, nor any of its terms or provisions, nor entry of the Judgment, nor any document or
exhibit referred or attached to the Stipulation, nor any action taken to effect the Stipulation, is, may be construed as, or may be used as evidence of the validity of any of the Released Claims or any admission by or against any of the Defendants
of any fault, wrongdoing, or concession of liability, or any infirmity in the defenses that could have been asserted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS OF THE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the proposed Settlement are set forth in the Stipulation, which has been filed with the Court and is available for
viewing on Walgreens&#146; website at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information. The following is only a summary of its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Settlement, Walgreens has agreed to implement and maintain the corporate governance reforms set forth in Exhibit A to
the Stipulation (&#147;Corporate Governance Reforms&#148;). The Corporate Governance Reforms shall be maintained by Walgreens for a period of not less than five (5)&nbsp;years. Walgreens and the Board acknowledge that the filing and prosecution of
the Derivative Action caused the Company&#146;s decision to adopt and implement the Corporate Governance Reforms. Walgreens and the Board also acknowledge and agree that the Corporate Governance Reforms confer a substantial benefit to Walgreens and
Current Walgreens Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporate Governance Reforms require: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>BOARD OF DIRECTORS</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <U>Mandatory Attendance of Directors at Annual Stockholder Meetings</U>. The Company shall revise its Corporate Governance Guidelines to
provide that, absent extenuating circumstances, its Chief Executive Officer and each member of the Board shall attend each annual stockholder meeting either in person or remotely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 6
 of 12 PageID #: 313 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Director Training and Continuing Education</U>. Section II of Exhibit A to the
Settlement Stipulation entered into in connection with the settlement of the action captioned <I>Cutler</I> <I>v. Wasson, et al.</I>, Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:14-cv-10408</FONT></FONT> (N.D. Ill.),
contemplates that the Company&#146;s directors and senior officers will receive training on &#147;disclosure-related laws, regulations, policies, and procedures&#148; in years one, three, and five of the implementation period of that settlement.
Pursuant to the settlement of this Action, the Company will cause those same directors and senior officers to receive that training on an annual basis (instead of the semi-annual basis contemplated by the settlement of the <I>Cutler </I>action), and
extend the implementation period of this settlement term (both for purposes of this action and the <I>Cutler </I>action) from five to six years such that those directors and senior officers will receive annual training of the type described above
for each year between 2024 and 2029. This training shall be virtual. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>AUDIT COMMITTEE</B>. The Company shall revise the Audit
Committee Charter to include the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <U>Purpose</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall assist the Board in its oversight over the soundness of the Company&#146;s systems of
internal accounting, financial controls, and disclosure controls. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <U>Composition</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least half of the members of the Audit Committee must qualify as an &#147;audit committee financial
expert&#148; as defined by the U.S. Securities and Exchange Commission (&#147;SEC&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <U>Specific Duties</U>:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall review and discuss with management and the Company&#146;s independent auditor on an
annual basis a plan to assess the adequacy and effectiveness of the Company&#146;s systems of internal accounting and financial controls, as well as any related impact on the Company&#146;s disclosure controls and procedures. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Audit Committee&#146;s periodic review of the adequacy and effectiveness of the Company&#146;s
disclosure controls and procedures, as provided by Specific Duty #16 in the current Audit Committee Charter, the Audit Committee shall meet periodically with either the Senior Officers, as defined in the Disclosure Committee Charter, or a
representative of the Disclosure Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures that the Disclosure Committee conducts prior to the filing of each of the
Company&#146;s annual and quarterly Exchange Act reports pursuant to the Disclosure Committee Charter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 7
 of 12 PageID #: 314 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Committee Reports, as provided by Specific Duty #20 in the current Audit Committee Charter, the
Chair of the Audit Committee shall periodically review with the Board any issues that arise with the quality or integrity of the Company&#146;s disclosure controls and policies, including any significant deficiencies or material weaknesses.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>DISCLOSURE COMMITTEE</B>. The Company shall revise the Disclosure Committee Charter to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either the Senior Officers, as defined in the Disclosure Committee Charter, or a representative of the
Disclosure Committee shall meet periodically, and in no event less than quarterly, with the Audit Committee to discuss material results of the Disclosure Committee&#146;s evaluations of the Company&#146;s disclosure controls and procedures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the Company is considering a potential merger, acquisition, or divestiture, the Disclosure Committee
shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluate material written disclosures filed with the SEC regarding any potential strategic transaction,
including potential mergers, acquisitions, divestitures, joint ventures, or reorganizations, prior to public disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meet as needed with pertinent senior management to discuss SEC disclosure obligations regarding any potential
merger, acquisition, or divestiture that the Company believes in good faith must be disclosed in its SEC filings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<B>WHISTLEBLOWER CONTROLS</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall amend its relevant whistleblower policies as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A log of whistleblower complaints regarding the Company&#146;s accounting practices, financial reporting, and
SEC disclosure and compliance obligations made either (i)&nbsp;internally by a Company employee through appropriate reporting channels, including, for example, through the Compliance and Ethics Hotline; or (ii)&nbsp;by an external party such as a
relator through a regulator, governmental authority, or pursuant to a qui tam complaint (the &#147;Whistleblower Complaints&#148;), as well as the results of all investigations of such Whistleblower Complaints, shall be maintained internally by, or
maintained externally by relevant third-party vendors with oversight from, the Global Chief Compliance and Ethics Officer (or the Vice President, Global Internal Audit, if necessary) for a period of not less than ten (10)&nbsp;years.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At or before each regularly scheduled Audit Committee meeting, the Audit Committee shall be provided with a
written summary of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 8
 of 12 PageID #: 315 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Whistleblower Complaints received by the Company that pertinent senior management considers to be material, as well as any information that pertinent senior management considers material
resulting from any internal investigation into such Whistleblower Complaints. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To more explicitly reflect that the Company considers it the duty of all employees to promptly report
compliance concerns to company leaders, Employee Relations, and the Compliance Office, and to more explicitly reflect that they should report such concerns without fear of reprisal or retribution of any kind. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISMISSAL AND RELEASES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Settlement is conditioned upon the occurrence of certain events, which include, among other things: (i)&nbsp;final approval of the
Settlement by the Court following notice to Current Walgreens Stockholders and the Settlement Hearing contemplated by the Stipulation; and (ii)&nbsp;Court entry of the Judgment, approving the Settlement and dismissing with prejudice the Derivative
Action, without awarding costs to any Party, except as provided herein (the &#147;Effective Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Effective Date,
Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged the Released Claims against the Released
Parties and their Related Persons. Walgreens, Plaintiff, and each of the Current Walgreens Stockholders shall be deemed to have, and by operation of the Judgment shall have, covenanted not to sue any Released Party or any of their Related Persons
with respect to any Released Claims, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting the Released Claims against any Released Party or any of their Related Persons or Defendants&#146; Counsel except to
enforce the releases and other terms and conditions contained in the Stipulation and/or the Judgment entered pursuant thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 9
 of 12 PageID #: 316 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Effective Date, each of Walgreens and the Individual Defendants shall be deemed to
have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged each and all of Plaintiff and Plaintiff&#146;s Counsel from the Released Defendants&#146; Claims. Walgreens and the Individual
Defendants shall be deemed to have, and by operation of the Judgment shall have, covenanted not to sue Plaintiff or Plaintiff&#146;s Counsel with respect to any Released Defendants&#146; Claims, and shall be permanently barred and enjoined from
instituting, commencing, or prosecuting Released Defendants&#146; Claims against Plaintiff or Plaintiff&#146;s Counsel except to enforce the releases and other terms and conditions contained in the Stipulation and/or the Judgment entered pursuant
thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VI.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PLAINTIFFS&#146; ATTORNEYS&#146; FEES AND EXPENSES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After negotiating the substantive terms of the settlement, Plaintiff&#146;s Counsel and Defendants&#146; Counsel separately negotiated the
amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel in recognition of the benefit provided to Walgreens and Current Walgreens Stockholders due to the Corporate Governance Reforms. The Parties have agreed that
Plaintiff&#146;s Counsel shall apply to the Court for the Fee and Expense Amount in the total amount of $750,000, which shall be Plaintiff&#146;s Counsel&#146;s sole application for an award of fees and expenses in connection with the Derivative
Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Plaintiff&#146;s Counsel have neither received any payment for their services in conducting the Derivative Action, nor
have counsel been reimbursed for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred. The Parties believe that the sum agreed to is within the range of attorneys&#146; fees and
expenses approved by courts under similar circumstances in litigation of this type. Walgreens stockholders are not personally liable for the payment of any award of attorneys&#146; fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 10
 of 12 PageID #: 317 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaintiff&#146;s Counsel may apply to the Court for a service award of up to $2,500 for
Plaintiff, only to be paid upon Court approval, and to be paid from the Fee and Expense Amount in recognition of Plaintiff&#146;s participation and effort in the prosecution of the Derivative Action. Neither Walgreens nor any of the Individual
Defendants shall be liable for any portion of the service award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Settlement Hearing will be held before the Honorable Gregory B. Williams, at the U.S. District Court for the District of Delaware, J. Caleb
Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801 (the &#147;Settlement Hearing&#148;), at which the Court will determine: (i)&nbsp;whether the terms of the Stipulation should be approved as fair, reasonable, and
adequate; (ii)&nbsp;whether the Notice fully satisfied the requirements of Rule 23.1 of the Federal Rule of Civil Procedure and the requirements of due process; (iii)&nbsp;whether all Released Claims against the Released Parties should be fully and
finally released; (iv)&nbsp;whether the <FONT STYLE="white-space:nowrap">agreed-to</FONT> Fee and Expense Amount should be approved; and (v)&nbsp;such other matters as the Court may deem appropriate. The Settlement Hearing may be continued by the
Court at the Settlement Hearing, or at any adjourned session thereof without further notice. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VIII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE RIGHT TO OBJECT AND/OR BE HEARD AT THE HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Walgreens Stockholder may object and/or appear and show cause, if he, she, or it has any concern why the Settlement should not be approved
as fair, reasonable, and adequate, or why the Judgment should not be entered thereon, or why the <FONT STYLE="white-space:nowrap">agreed-to</FONT> Fee and Expense Amount should not be approved. However, unless otherwise ordered by the Court, you
shall only be heard or entitled to contest the approval of the terms and conditions of the Settlement, or, if approved, the Judgment to be entered thereon approving the same, or the amount of attorneys&#146; fees and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 11
 of 12 PageID #: 318 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement of expenses to Plaintiff&#146;s Counsel, unless you have, <B><I>at least fourteen (14)</I></B><B><I></I></B><B><I>&nbsp;calendar days prior to the Settlement Hearing</I></B>, filed
with the Court a written notice of objection containing the following information: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Your name, legal address, and telephone number; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The case name and number (<I>Clem v. Skinner, et al.</I>, Case No. <FONT STYLE="white-space:nowrap">1:21-cv-00406);</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Proof of being a Walgreens stockholder currently and as of July 9, 2024; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The date(s) you acquired your Walgreens shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. A statement of each of each objection being made; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Notice of whether you intend to appear at the Settlement Hearing (you are not required to appear); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Copies of any papers you intend to submit to the Court, along with the names of any witness(es) you intend to call to testify at the
Settlement Hearing and the subject(s) of their testimony. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOUR WRITTEN OBJECTIONS MUST BE POSTMARKED OR ON FILE WITH THE CLERK OF THE
COURT NO LATER THAN JANUARY 9, 2025. Only stockholders who have filed and delivered valid and timely written notices of objection will be entitled to be heard at the Settlement Hearing unless the Court orders otherwise. All written objections and
supporting papers must be filed with the Clerk of the Court, U.S. District Court for the District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801, and serve such materials by that date, to
each of the following Settling Parties&#146; counsel: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Counsel for Plaintiffs:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Counsel for Defendants:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>COOCH AND TAYOR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ABRAMS &amp; BAYLISS LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Blake A. Bennett</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: A. Thompson Bayliss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Brandywine Building</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">20 Montchanin Road</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1000 N. West Street, Suite 1500</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Suite 200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Wilmington, DE 19801</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wilmington, DE 19807</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone: (302) 984-3800&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (302) 778-1033</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"> Case 1:21-cv-00406-GBW&#8195; Document 48&#8195; Filed 11/22/24&#8195; Page
 12
 of 12 PageID #: 319 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E-mail: <U>bbennett@coochtaylor.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Bayliss@AbramsBayliss.com</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ROBBINS LLP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ROPES &amp; GRAY LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Stephen J. Oddo</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: Martin J. Crisp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5060 Shoreham Place, Suite 300</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1211 Avenue of the Americas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">San Diego, CA 92122</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10036-8704</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone: (619) 525-3990</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (212) 596-9000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E-mail: <U>soddo@robbinsllp.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">E-mail: <U>Martin.Crisp@ropesgray.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise ordered by the Court, any Current Walgreens Stockholder who does not make his, her, or its
objection in the manner provided herein shall be deemed to have waived such objection and shall forever be barred and foreclosed from making any objection to the fairness, reasonableness, or adequacy of the Settlement, or to otherwise be heard, and
shall otherwise be bound by the Judgment to be entered and the releases to be given. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IX.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXAMINATION OF PAPERS AND INQUIRIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is additional information concerning the Settlement available in the Stipulation, which is available for viewing on Walgreens&#146;
website at https://investor.walgreensbootsalliance.com/investor-resources/shareholder-derivative-settlement-information. You may also inspect the Stipulation during business hours at the office of the Clerk of the Court, U.S. District Court for the
District of Delaware, J. Caleb Boggs Federal Building, 844 N. King Street, Unit 26, Room 6124, Wilmington, DE 19801. Or you can call Robbins LLP, Stephen J. Oddo, telephone: (619) <FONT STYLE="white-space:nowrap">525-</FONT> 3990, for additional
information concerning the settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE DO NOT CONTACT THE COURT OR WALGREENS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGARDING THIS NOTICE. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATED:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BY ORDER OF THE COURT UNITED STATES DISTRICT COURT OF THE DISTRICT OF DELAWARE</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>wba-20241125.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/29/2024 7:22:16 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:wba="http://walgreensbootsalliance.com/20241125"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://walgreensbootsalliance.com/20241125"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20241125_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20241125_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20241125_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="wba_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" name="M3.600WalgreensBootsAllianceInc.NotesDue2025Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" name="M2.125WalgreensBootsAllianceInc.NotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>wba-20241125_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/29/2024 7:22:18 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wba-20241125.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="wba-20241125.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:loc xlink:href="wba-20241125.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="wba_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>wba-20241125_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/29/2024 7:22:16 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="wba_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="wba_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="wba-20241125.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</link:label>
    <link:loc xlink:href="wba-20241125.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>wba-20241125_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/29/2024 7:22:16 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wba-20241125.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="wba_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20241125.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="wba_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20241125.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20241125.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46799836162768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001618921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WALGREENS BOOTS ALLIANCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1758322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Wilmot Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Deerfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-3700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member', window );">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.600% Walgreens Boots Alliance, Inc. notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member', window );">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.125% Walgreens Boots Alliance, Inc. notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wba_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wba_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF>2'*\Y@[VP_ .\OH$RO)_;A>/';1N\?4$L#!!0    ( '" ?5F?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( '" ?5D'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ <(!]61V5_//N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ <(!]69E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !P
M@'U9^<S)!S$%  #G&   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ <(!]69^@&_"Q @  X@P   T
M         ( != T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !P@'U9EXJ[
M',     3 @  "P              @ %0$   7W)E;',O+G)E;'-02P$"% ,4
M    " !P@'U9'#AEZC\!   \ @  #P              @ $Y$0  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ <(!]620>FZ*M    ^ $  !H
M     ( !I1(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ <(!]6660>9(9 0  SP,  !,              ( !BA,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  U!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d898694d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d898694d8k.htm">d898694d8k.htm</File>
    <File>wba-20241125.xsd</File>
    <File>wba-20241125_def.xml</File>
    <File>wba-20241125_lab.xml</File>
    <File>wba-20241125_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d898694d8k.htm": {
   "nsprefix": "wba",
   "nsuri": "http://walgreensbootsalliance.com/20241125",
   "dts": {
    "inline": {
     "local": [
      "d898694d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "wba-20241125.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "wba-20241125_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "wba-20241125_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wba-20241125_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-11-25_to_2024-11-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d898694d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-11-25_to_2024-11-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d898694d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "wba_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://walgreensbootsalliance.com/20241125",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "wba_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://walgreensbootsalliance.com/20241125",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://walgreensbootsalliance.com/20241125",
     "localname": "M2.125WalgreensBootsAllianceInc.NotesDue2026Member",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]",
        "terseLabel": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://walgreensbootsalliance.com/20241125",
     "localname": "M3.600WalgreensBootsAllianceInc.NotesDue2025Member",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]",
        "terseLabel": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://walgreensbootsalliance.com//20241125/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-24-268088-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-268088-xbrl.zip
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M'B<]!9WMH/4ME"C)EH)!D/&J#O7]^TY+">M[9<C]<8VJZ/6$J]]_8;TVDT>
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MG51$"S(<V"5:3,0&!=B'PT:]3X9-D?@=1JI+U9+98I_GJSQ+M&N5HA;>R$;
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MIP437)B?L"=X.(45^D?0BZ?O\#$_<Z5$[:+YH?7/%Q%N**S;R7'CZ\CO^8E
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MS :OYQ5"DM-,[N"=Z/, X1'$V6,O=B3/RXAX>$,"'!2&-M:KC>MRB[* ![W
MU=0WB_0@BC/$#K\Y0^S'9GI9*6395+-L*IK-X)2Z3JQ0_%,4*>Q:!9<W[P%O
MM%51Q2B9YX%B6*NPKF<T5_N*[S.J'G#LWXG%H9VY_025""2<ZRCL>X-9!!]/
MW/Z7&Q"=\*U24XU^K;3K L7UX&?HK=6*N K$I1OU1TP_NU741:N@D9Y*40YL
MP%(5\M3*@W>QNEHK"G ^>BJKS=R.#"2E*+EPR"9TNL)R"8@!]0C1!_X'-Q@.
MIG4B?%,O#+\P.V -(Q;3613/Z-"%XE"\;Q[7O7$%5=3WKYO'<-O!FW=B9V<;
M#R=IWDD()WH2!C<B),4*3G9P@Z<<-*0;^'WHCD&TX1N GP#;&L#/0+UP+Q[A
M&)YS ]HD?ND"EPNG(?(U8"VH\2J=W)HB/*?M)W#00?\]-7Z<<DFNI?I1JVI&
M_=+W7=+3<Z[H>,0^>/-PDG5:3WEE!>2%)PJN@?G&(9BHH,@E:I'%0,IM>Y83
M-P%V%HM98%:0F7IZ>,S#'I-\=] ,&8/TP&'BB+RO'I@&) * QR.+'OKX:!]$
M:0(20EEDCK5!L(6#&9Q04=W>3\U_V5Q!FI+>"[+(DY>42P4+O<#;?_:R[)I3
M+:IL7,*Q-H=X2'J8"S0=]K^,PC&85G .M41R^RS?M/8"1PIM2CQ.^/>M92%Z
M2:5<<L?X4\5Y6MFC]C%9D+?J*,$VXE4? Q_WNH.'/!9U/TXBOY^P\D0<D(2V
M^CH<HN$E7;,O;>L-+E=/=F]0.4@LP^K1Z6!/TL$<*$!1@=8)M2_!17T)20!8
MW%P=I(4%TURV7 )R=\5?(1 3W&+T(::JC')IK<Z9'\%RV!H4/ A6?*Y6; ;4
M.>9C[$9C'T8$AU@[-V"8,.)HSMJ;'#*KG\2*00E;23B@DV[!%B*],HF Q@KL
MVZ=Y3D)6+8$D7) !),#'\RW)!\JE&%@+J(\X*] 10<W-/2<C4/T3/!<PHHJ
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MY%W8Y*G7]X?HN<?,J<+MI,P'9&X%FP9K8!&T#-&G?'>9']7^D.F%V1/]\6R
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MGQCY-R,"Q:42-[CT)H*-H$+T_.<YPM23%\V+K?<QP5;8,U37R#A&9I7DV1V
MC&:<6[I:*70Y*Z43IR20REF.2HM&G MSFHY0I9-4SS=(LC?9D;+DQ 9=D'.E
M5$AX9C#F8PLOGS$EK60\,I0W=><, TZ@*;$7W2(M(N0>:!8U>*$) >$M5!6H
M?5%R,#@]+_%UY84K[F3^)<9G_# "31BNH% -'<YPC$52!DD9LY;,W3E#=V"N
M<<(.;C4#)S,%L3@#)[6(-&30!SA<0^[L*1 L+6UJ)^G\]8"4:9.)%3VZPCE2
MG%"-*D?5#&CM5<&FPE:18BK";-LHP]&7\C3-QN#P&.;&/.W1Y^^K^;>(.R[,
M7C)-=#8MCQ$I]&F[%.AA:W#RJ];@+[4&;.&]C%]EU!*KP823ZET$E.U&20"W
MC?RI(Q +!'EG[I<F+MA7R8=N'(=]7UK;JB(9K5Y]A4?9F([,58L\S-F$.9*B
M IPXFL6PS#,X[;JH:I!^*E=8:0:,C";$<&D?'@?;@]-2R=^@=F+OBT1YO)2K
MK#>+L<*96!F-HUS"?,5$QE='&"6COA-^HID%Z&3Q-)P1^\!/\)^U-9\.-^;3
M&IA/U6W"L=T_$K;]M/,$[*<'QK3@B \H!23$4X.1X0"!>MV$/L>SOOX-V RG
M:2.?]0>^&U$\!?6F,98*QDZ&8_#Q!/Z <17O%WAXOVA.NQ1PO<B5=1J&Z.<!
MIM-UY^,02T@JM8HC?5B]'G8OT%ZKQYS76,]+ T+-14VA-EG@/M;,I(IW#QFI
M(A-&5)XZ4OM0L$:V\D$DM !+I91E6SZS[Y-_ 3W7&$@9'VO/LVJ>5VD",N7?
M8%WD.VP??Y,F:I,R#EU[9ZB8@X^Z-&>Q0H,RQ"@F;-0 ,@/T9T7&6NC!X#%
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M=BN121#&6M#-SRB!F!(+J#\HE^J#YLX]2&62<*8MI97D9Z]MJD(_U1QHG2V
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MU9XJN[6Q'5+EM"LC5TXJ&5(;LNQ*_ 6:W<X];#$N%5$#SYP9^)_/&KY6)MQ
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M)51\QD82D*\D.&NM=,)4(LT+@?,A9*[ZU>JN8DG-91U'Y8TLS%W]M;D;&'S
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MUT3N:CKIQUVUNK4F7-&\O+YJ=VLPOF8+FS[0,$3MY.IC%Y_8%NWFA_-NA]Y
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MB(..>>J%K2 )^R'R_H*[<$1G5(I%V?*PF2ZQS3AQDU03EPEV:,(<_^ 6AV+
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MX.P1; QW<H E(J_-=.JYV';4D 0YK3!ZIR _//;KS7 U$81*A+,$["A/@W,
MR_ZBO"EC7Z'..(+<)SXA55$O<T3]^UHN<9 BUHA]!9X3]?2!CRX_1+J1BSF
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M&O8%Z)7&YH!^!"HI$B/U,*3'4C.JQE<ZA+>>;D"%U$Z-@2;>I&>JF/ELT.!
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M9I H"/33J3#A)5H[NHBR[(T@#(UIWV>O)K41\M+?X%IAT[P$+(!?*@WS^*Y
MY:=N%1B<I ,(+R+I(DW;<ZC,(RP]Y*^Q]%$2BB86U>$EPF64V3M1.2Y*^]2/
M&\@B+Y=Y3/E=6/0M^NKYQ\_(8[JO'YZ]?KCTQ^96#QM_Z'>ELHYY;,Q,W^OW
M1I5WNI?*__=0JI8VIM6]CL<4&UC-%B\S)<3.$ Y45/PFX96]@("DWI11W(<
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M%ZKZ780\NJ _WI9J$:;XI8LA'2N^W6[/QR:G FP"V_>7?.-\EMW!Y\TV8C#
MFV9KR3?D\B:_%G%SNFIQ\X:FAM-3\.FRAX<1[VQI<DELJM_UAF=V??$J(F@2
MT,F4.RBFS8U1NKZI__.WLZB=%;Z-3B[8DB"%\IN-?#:7Q*A6"H52>;7R(4:
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M0HQ'SZ\XJY0'A<E/:]#5%:E"E4:-AX$P8X0DS"M.:<$]FL9<9B%G+-:E660
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M$F%DGN(/F8%'^)Y-\Q:SFL!7'"FXKG*3R,T6E^7NL8/,AW6T8#I80(/<.U1
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M*^%5[G" ;/^<)6?N(=<LM (C/##'QN9N^JO"3UA= =<X$8UY;)A=Z/.)>GG
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M&K1]9"0$D\ 2P+!/>"H"+!*[*K+.3]?W41O=[_R/'(]^_J94XG//=K.([E!
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M"\=^2EQ6#VJM5NV82K*ZQD6K/1V9NQ\.JP=&M6V<=-@_[-'X&ZL:%PVKTV'
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MJ_"[;C:,<Z-MSC7"WV:TN')3M!BXO56_@(O'W9/&P?\#4$L#!!0    ( '"
M?5FJ5#I<+ 0  ' 1   0    =V)A+3(P,C0Q,3(U+GAS9,U7WV_;-A!^+]#_
M@=73!DRB92_I(L0ITKDI#"19D:;;W@)*.MO$*%(CJ3CY[W>D)%O^$==QNG5Y
M"<V[[^Z^N^.1.GWW4 AR#]IP)8=!'/4" C)3.9?385"9D)F,\^#=V>M7IV_"
MD(PNQM<D)#-K2Y-0.I_/HWS"I5&BLFC!1)DJ* G#5O_7VR_D]]IZ0FY  #-
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MYI<X:_\LKW^[]/(+'77Q+U!+ P04    " !P@'U9O)&W> X(  !06@  %
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M.#8Y-&1E>#DY,2YH=&U02P$"% ,4    " !P@'U9^ 4.P+(H  #K\@  $0
M            @ $VI   9#@Y.#8Y-&1E>#DY,BYH=&U02P$"% ,4    " !P
M@'U9JE0Z7"P$  !P$0  $               @ $7S0  =V)A+3(P,C0Q,3(U
M+GAS9%!+ 0(4 Q0    ( '" ?5D[O+R5[P4  .TU   4              "
M 7'1  !W8F$M,C R-#$Q,C5?9&5F+GAM;%!+ 0(4 Q0    ( '" ?5F\D;=X
M#@@  %!:   4              "  9+7  !W8F$M,C R-#$Q,C5?;&%B+GAM
M;%!+ 0(4 Q0    ( '" ?5FCVCDNJ 4  +8Y   4              "  =+?
L  !W8F$M,C R-#$Q,C5?<')E+GAM;%!+!08     !P ' +X!  "LY0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d898694d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:wba="http://walgreensbootsalliance.com/20241125"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wba-20241125.xsd" xlink:type="simple"/>
    <context id="duration_2024-11-25_to_2024-11-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-293">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-11-25_to_2024-11-25"
      id="Hidden_dei_EntityCentralIndexKey">0001618921</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-328">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-329">2024-11-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-330">WALGREENS BOOTS ALLIANCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-331">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-332">001-36759</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-333">47-1758322</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-334">108 Wilmot Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-335">Deerfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-336">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-337">60015</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-338">(847)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-339">315-3700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-340">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-341">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-342">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-343">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-344">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-345">WBA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-346">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-347">3.600% Walgreens Boots Alliance, Inc. notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-348">WBA25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-349">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-350">2.125% Walgreens Boots Alliance, Inc. notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-351">WBA26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-11-25_to_2024-11-25_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-352">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-11-25_to_2024-11-25" id="ixv-353">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
